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CHAPTER I 
 
 
INTRODUCTION 
 
Obesity has become a major health problem worldwide. Its prevalence has doubled the 
last two decades [1]. An estimated 200 million men and nearly 300 million women were obese in 
the year 2008 [2]. According to the National Health and Nutrition Examination Survey 
(NHANES), in the United States alone, more than ⅓ or 35.7% of the adult population (20 years 
and above) and 16.9% of the children and adolescents (2 – 19 years old) were obese in 2009 - 
2010 [3]. This represents 40.6 and 37.5 million of adult women and men, respectively, and 5.5 
and 7.0 million girls and boys, respectively.  
The World Health Organization (WHO) defines obesity as a disorder when excessive fat 
is accumulating in the body, such that it may bring adverse health effects [2]. Obesity is mainly 
caused by imbalance of energy intake, where more energy is consumed than is expended [4]. 
Diets high in calories and fat content have been shown to increase body weight and body fatness 
[5].  
Body mass index (BMI) is a commonly used screening tool to assess obesity in a 
population. It is calculated as weight in kilograms divided by height in meters squared. 
Individuals with BMI of 18.5 - 24.9 kg/m
2
, 25 - 30 kg/m
2
, and >30 kg/m
2
 are categorized as 
normal, overweight, and obese, respectively. Although BMI does not directly measure body 
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fatness, it is a relatively reliable indicator of body fatness for most people, as BMI correlates to 
direct measures (i.e. underwater weighing and dual energy x-ray absorptiometry (DXA)) of body 
fat [4]. High BMI is also associated with obesity-related morbidities, such as high blood pressure 
and high blood cholesterol level [6], indicating its relevance as a measure of body fatness. 
Besides BMI, waist circumference can also be used to assess obesity. A waist circumference 
greater than 40 inches in men and 35 inches in women indicates central adiposity, and it is one of 
the indicators for metabolic syndrome [7].  
Alongside the increased prevalence of obesity is an increased incidence of many chronic 
conditions. Obesity is shown to be a risk factor to many chronic diseases, such as stroke, coronary 
heart disease, gallbladder disease, osteoarthritis, certain types of cancer, hypertension, type 2 
diabetes mellitus, and dyslipidemia [4]. The relationship between obesity and type 2 diabetes is 
especially strong. Obese individuals were found to be 1.65 times more likely than normal weight 
individuals to develop type 2 diabetes [8].  
Because of the increased prevalence of obesity, the number of cases of type 2 diabetes 
has also increased. The Centers for Disease Control and Prevention (CDC) defines diabetes as a 
group of diseases marked by high blood glucose levels due to impaired insulin production and/or 
impaired insulin action to signal cells to uptake glucose [9]. Worldwide, more than 346 million 
people have diabetes [10]. In the United States, diabetes is affecting 25.8 million individuals or 
8.3% of the population [11]. Research showed that diabetics had 50% greater mortality risk than 
people without diabetes of similar age. The estimated direct and indirect costs for diabetes were 
$176 billion in 2007 [11]. 
Due to the prevalence and severity of diabetes, pharmaceutical companies have 
developed numerous drugs to lower blood glucose level. There are six classes of oral medications 
for diabetes that are sold in the United States: biguanides, thiazolidinediones, sulfonylureas, 
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alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors (DPP4-inhibitors), and 
meglitinides [12]. They work through different mechanisms in lowering blood glucose levels in 
diabetics.  
Biguanides, such as metformin are suggested to reduce hepatic glucose output, increasing 
insulin action and insulin-mediated glucose utilization in peripheral tissues [12, 13]. However, 
based on the review by Lorenzati et al.[13], the use of metformin is associated with some side 
effects, including metallic taste, mild anorexia, nausea, and diarrhea. Sulfonylureas, on the other 
hand, are proposed to work by stimulating insulin release from pancreatic β-cells [12], and to a 
lesser extent by improving insulin resistance in peripheral tissues [13]. Side effects associated 
with sulfonylurea use include hypoglycemia and weight gain [13]. Alpha-glucosidase inhibitors 
inhibit the breakdown and absorption of carbohydrates [12], but are associated with flatulence, 
abdominal discomfort, bloating, and diarrhea [13]. In contrast, DPP4-inhibitors act by stimulating 
insulin secretion, inhibiting glucagon secretion, and possibly preserving β-cell mass and 
inhibiting apoptosis of β-cell [13]. DPP4-inhibitors are associated with increased risk for 
infection, headache, back pain, and osteoarthritis. Alternatively, meglitinides stimulate insulin 
release from pancreatic β-cells [12], but are associated with hypoglycemia [13]. 
Thiazolidinediones (TZDs), such as rosiglitazone, increase insulin sensitivity [12, 14] by 
increasing glucose uptake and utilization by muscle and adipose tissues, and inhibiting hepatic 
gluconeogenesis [13]. However, the use of rosiglitazone is associated with some side effects 
including edema [15-18], weight gain [15, 16, 19], fractures [20-22], congestive heart failure [15, 
23, 24], myocardial infarction [25, 26], and increased risk of death from cardiovascular causes 
[25]. 
Because of the deleterious side effects associated with rosiglitazone and other 
pharmacological agents, natural food products are being investigated for their possible beneficial 
effect in lowering blood glucose level. Fruits, like mangos, were demonstrated to have glucose-
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lowering effects [27-39] possibly due to fiber, vitamins, minerals and other bioactive compounds 
[40]. Most of the studies investigating the glucose-lowering properties of mango were done using 
its extract especially from the stem bark, which is rich in mangiferin. Mangiferin, a phenolic 
compound found in mango [41], when administered orally to streptozotocin (STZ)-induced 
diabetic rats was shown to significantly decrease blood glucose level [33]. 
Only a few studies have been done to investigate the health benefits of the mango fruit 
(pulp). Perpetua and Salgado [38] found that alloxan-induced diabetic rats when fed diet 
containing 5%, 10%, and 15% (by weight) of mango flour for 30 days had significantly lower 
blood glucose levels compared to the control group. An earlier study by Lucas and colleagues [39] 
compared the glucose-lowering properties of two doses of freeze-dried mango pulp powder (1% 
or 10%) to that of rosiglitazone in mice fed high fat diet. They found that mango supplementation 
was able to reduce blood glucose and improve lipid profiles in mice fed high fat diet. 
The aim of this study is to investigate the effectiveness of mango (1% or 10% by weight) in 
combination with a lower dose of rosiglitazone (25 ppm) compared to a higher dose of 
rosiglitazone (50 ppm) alone in lowering blood glucose concentrations and modulating body 
composition and other clinical parameters in mice fed high fat diet. Since rosiglitazone was 
shown to be associated with some side effects, a lower dose of rosiglitazone could potentially 
reduce or delay the side effects associated with the use of higher doses of rosiglitazone. Our null 
hypothesis is that a lower dose of rosiglitazone (25 ppm) when combined with mango will not be 
as effective as rosiglitazone alone (50 ppm) in lowering blood glucose level and modulating body 
composition and other clinical parameters in mice fed high fat diet. The present study also sought 
to confirm the earlier findings by Lucas and colleagues [39] on the effectiveness of freeze-dried 
mango pulp powder (1% and 10%) in lowering blood glucose concentrations compared to the 
drug rosiglitazone in mice fed high fat diet.  
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
Type 2 diabetes 
Prevalence and cost 
Worldwide, more than 346 million people have diabetes [10]. In the United States (U.S.) 
alone, diabetes is affecting 25.8 million people or 8.3% of the population [11]. In the year 2010, 
about 1.9 million and 79 million Americans were newly diagnosed with diabetes and prediabetes, 
respectively. Prediabetes is a condition when the fasting plasma glucose or hemoglobin A1c 
levels (HbA1c) of an individual are between 100 - 125 mg/dL or 5.7% - 6.4%, respectively. 
People diagnosed with prediabetes have an increased risk of developing type 2 diabetes. 
Additionally, gestational diabetes cases were reported to be 2% - 10% of all pregnancies in the 
U.S. Research showed that women that had gestational diabetes have a 35% - 60% chance of 
developing diabetes in the next 10 - 20 years [11].  
The mortality rate and medical cost due to diabetes is also increasing. Diabetes is the 
seventh leading cause of death, and was responsible for 71,382 deaths in the U.S. in 2007 [11]. 
Diabetics were found to have 50% greater mortality risk than non-diabetics of similar age. The 
estimated total direct and indirect medical cost for diabetes was $174 billion in 2007 [11]. The 
projected diabetes related medical cost for the year 2032 is $336 billion [42]. Moreover, 
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according to CDC, individuals diagnosed with diabetes have to spend twice as much on medical 
expenses as individuals without diabetes.  
In addition to high prevalence and cost, diabetes also leads to detrimental health 
complications. There are two primary types of diabetes-related complications: macrovascular and 
microvascular complications. Macrovascular complications are large-vessel diseases, including 
coronary heart disease and stroke [43]. On the other hand, microvascular complications are 
diseases affecting the small vessels, including diabetic retinopathy, nephropathy, and neuropathy.  
Both macro- and microvascular complications increase the risk of death and 
hospitalization in diabetes [44]. Young and colleagues [44] reported that the hazard ratio of 
mortality risk associated with two diabetic complications was 1.90, three complications was 2.66, 
four complications was 3.41, and five or more complications was 7.18. On the other hand, the 
hazard ratio of hospitalization risk associated with diabetic complications was 1.48 for one 
complication, 2.27 for two complications, 3.12 for three complications, 4.13 for four 
complications, and 6.56 for five or more complications [44].  
Diabetes is also associated with 2- to 4-fold increased risk of cardiovascular diseases 
(CVD) when compared to non-diabetic individuals [45]. In 2004, 68% of heart disease deaths and 
16% of stroke deaths reported among people aged 65 years or older were related to diabetes [11]. 
Also, CDC reports that diabetic adults have 2 to 4 times higher heart disease mortality rates and 2 
to 4 times higher risk for stroke than non-diabetic adults. The risk of coronary artery disease 
increases even further with poorly controlled diabetes because insulin resistance can accelerate 
atherogenesis. Good glucose control: (1) HbA1c level <7%, (2) fasting plasma glucose <100 
mg/dL, and (3) non-fasting glucose level <140 mg/dL as recommended by the American Diabetic 
Association, as well as good lipid control: (1) low-density lipoprotein cholesterol (LDL-C) <100 
mg/dL, (2) triglycerides (TG) <150 mg/dL, and (3) high-density lipoprotein cholesterol (HDL-C) 
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>50 mg/dL for women and >40 mg/dL for men, as recommended by the National Cholesterol 
Education Panel, can reduce the incidence of CVD.  
Aside from getting macrovascular complications, diabetics are also prone to 
microvascular complications, such as diabetic retinopathy, nephropathy, and neuropathy. Diabetic 
retinopathy is defined as damage to the eye’s retina that occurs with chronic diabetes [46]. It is 
characterized by signs or symptoms of retinal ischemia and increased retinal vascular 
permeability [47]. Diabetic retinopathy is the most common microvascular complication in 
diabetes [48], and the leading cause of blindness in the U.S. [47]. Every year, diabetic retinopathy 
results in nearly 10,000 new cases of blindness [48]. In 2005 - 2008, 25.8% or 4.2 million 
diabetics aged 40 years or older had diabetic retinopathy [11], and it is projected to increase to 16 
million in 2050 [49]. The direct medical cost of diabetic retinopathy was approximately $500 
million among American adults (≥40 years old) in 2004 [49]. The risk of developing diabetic 
retinopathy depends on the severity of hyperglycemia and the presence of hypertension. Adiga 
and colleagues [50] found that patients with diabetic retinopathy had the highest blood glucose 
and HbA1c levels among the other diabetic complications (i.e. foot ulcers, nephropathy, and 
urinary tract infection). The authors suggested that these results imply that poorer glucose control 
increases the risk of developing diabetic retinopathy.  
Diabetic nephropathy is kidney disease or damage due to diabetes [51], and is 
characterized by the presence of microalbuminuria (≥300 mg/24 h) [52]. It is the leading cause of 
renal failure in the U.S. [48], affecting 30 - 50% of all diabetics [53], and accounted for 44% of 
all new cases of kidney failure in 2008 [11]. In 2008, an estimated 48,374 diabetics had to begin 
treatment for end stage kidney disease, and a total of 202,290 diabetics with end stage kidney 
disease were living on chronic dialysis or with a kidney transplant, indicating the severity and 
prevalence of this complication. 
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On the other hand, diabetic neuropathy is damage to the nervous system due to 
hyperglycemia in diabetes [54]. Approximately, 60 - 70% diabetics had mild to severe forms of 
nervous system damage [11]. Almost 30% of diabetics aged 40 years or older had impaired 
sensation in the feet, and the severe forms of diabetic neuropathy are a major contributing cause 
of lower-extremity amputations. In 2006, about 65,700 lower-extremity amputations were 
performed in diabetics; inferring diabetic neuropathy causes detrimental impact on diabetics. 
The statistics discussed above show that diabetes-related macro- and microvascular 
complications are severe, and they are the common cause of deaths in diabetic patients. Due to 
their association with the severity and duration of diabetes, good glucose control is crucial to 
prevent or delay these detrimental complications. Hence, treatments that can help diabetics to 
maintain good glucose control or improve hyperglycemia will be beneficial in delaying or 
preventing the development of diabetes associated complications. 
 
Pathophysiology of type 2 diabetes 
 CDC defines diabetes as a group of diseases marked by high blood glucose levels, which 
result in impaired insulin production and/or insulin action [9]. Insulin from the pancreatic β-cells 
helps to modulate blood glucose during the fed state. According to the National Institutes of 
Health (NIH), diabetes is diagnosed when the fasting blood glucose level of an individual is 
above 126 mg/dL on two occasions [55]. Aside from fasting blood glucose as a diagnostic tool 
for diabetes, the American Diabetes Association (ADA) also recommended the blood glycated 
hemoglobin A1c (HbA1c) test as the alternate diagnostic test for diabetes. The HbA1c test 
monitors long-term blood glucose control while fasting blood glucose indicates current glucose 
control. Individuals with a HbA1c concentration greater than 6.5% are diagnosed as diabetes. The 
combination of these two diagnostic methods is a strong indicator of glucose control in diabetes. 
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Type 2 diabetes mellitus is a disease manifested by impaired insulin secretion, insulin 
resistance, and increased hepatic glucose production due to increased glycogenolysis and 
gluconeogenesis [56]. Under normal condition, glucose level increases following a meal, and this 
stimulates insulin release from the pancreatic β-cells. Insulin binds to cell surface receptors 
(insulin receptor) and causes phosphorylation of the β-subunit of the receptor, resulting in an 
increase in insulin receptor tyrosine kinase activity. Increase in tyrosine kinase activity enhances 
the phosphorylation of various endogenous protein substrates (e.g. insulin receptor), resulting in a 
cascading sequence of reactions responsible for the synthesis of RNA, DNA, protein, and 
intracellular enzymes that affect glucose metabolism. In the fed state, insulin enhances glucose 
uptake by the peripheral tissues and suppresses hepatic glucose output from glycogenolysis and 
gluconeogenesis. During fasting, the inhibitory effect of insulin is removed and hepatic glucose 
production via glycogenolysis and gluconeogenesis is enhanced. 
 The normal regulation of glucose is disrupted in type 2 diabetes. In type 2 diabetes, 
insulin-mediated glucose disposal by muscle is reduced, a result of impaired muscle glucose 
uptake [57]. In addition, glucose production by liver is increased despite elevated insulin level 
[56]. This phenomenon of hyperglycemia and hyperinsulinemia exemplifies insulin resistance in 
both muscular and hepatic tissues [57]. The progression of insulin resistance results in β-cell 
deterioration and impaired insulin secretion and release in addition to continuous hepatic glucose 
production [56]. Glycogen synthesis, glucose oxidation, and tissue glucose uptake are all 
impaired in type 2 diabetes.  
As a part of impaired glucose metabolism, glucose transport is also impaired in type 2 
diabetes. The glucose transporter, GLUT-4, is abundant in adipose cells, skeletal and cardiac 
muscles [56]. Under normal circumstances, insulin stimulates GLUT-4 translocation to the 
plasma membrane, resulting in glucose transport across the plasma membrane, a rate-limiting step 
for glucose metabolism [58]. In type 2 diabetes however, this translocation of GLUT-4 
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transporters to the plasma membrane is impaired. As a consequence, there is a decreased uptake 
of glucose into the cell and resistance to insulin-stimulated glycogen synthesis in the muscle, 
resulting in an accumulation of glucose in the blood, and hence hyperglycemia.  
In addition to glucose, lipid metabolism is also affected by diabetes. Increased release of 
free fatty acids from adipose cells due to enhanced lipolysis contributes to insulin resistance [59]. 
Elevated serum free fatty acid increases hepatic gluconeogenesis [60] through the production of 
acetyl-CoA derived from free fatty acid oxidation [61]. In the skeletal muscle, elevated free fatty 
acids impair glucose metabolism by competing with glucose as energy substrates through the 
Randle cycle [62]. Long-term exposure of β-cells to elevated free fatty acids also impairs the 
insulin secretory response to glucose [60].  
 
Contributors to the development of type 2 diabetes 
Dietary fat intake 
Dietary fat intake is shown to be a risk factor for the development of type 2 diabetes [63]. 
Thanopoulou and colleagues [63] reported that individuals with recently diagnosed diabetes and 
with fasting hyperglycemia had higher intake of total dietary fat (especially animal fat) and higher 
fat percent contribution to the energy intake compared to control even after the adjustment for all 
contributing variables. Another study conducted by Marshall and colleagues [64] found that fat 
consumption significantly predicted type 2 diabetes risk in individuals with impaired glucose 
tolerance. They reported that a 40 g increase in fat intake per day was associated with 3.4-fold 
increase in the risk of type 2 diabetes after adjusting for contributing variables. Furthermore, trans 
fatty acid intake was also positively associated with the risk of diabetes in age- and BMI-adjusted 
analyses [65]. These findings show that total dietary fat intake could lead to and be used as a 
predictor for future type 2 diabetes incidence.  
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Obesity 
Obesity is also found to be a risk factor for diabetes. The World Health Organization 
defines obesity as a disorder when excessive fat is accumulating in the body, such that it may 
bring adverse health effects. Body mass index (BMI) is a commonly used screening tool to assess 
obesity in a population. It is calculated as weight in kilograms divided by height in meters 
squared. Individuals with BMI of 18.5 - 24.9 kg/m
2
 are categorized as normal, BMI of 25 kg/m
2
 
and above are overweight, and BMI of 30 kg/m
2
 or greater are obese. Although BMI does not 
directly measure body fatness, it is a relatively reliable indicator of body fatness for most people, 
as it is correlated to direct measures (i.e. underwater weighing and dual energy x-ray 
absorptiometry (DXA)) of body fat [4]. The CDC reported that 86.3% and 84.2% obese men and 
women, respectively, also had diabetes [66] 
Mokdad et al. [67] found that increased BMI was associated with increased diabetes risk. 
They reported that obese adults with BMI of 40 or greater were significantly associated with 
diabetes with odds ratio of 7.37 when compared to normal weight adults. Bray et al. [68] found 
that baseline BMI and central adiposity (measured by waist circumference, waist-height-ratio, hip 
circumference, and waist-hip-ratio) predicted the development of diabetes in both genders. 
Among women, visceral adipose tissue to subcutaneous adipose tissue ratio was found to be a 
significant predictor for diabetes. In contrast, visceral adipose tissue, waist circumference, BMI, 
waist-height-ratio, and waist-hip-ratio predicted diabetes development in men. Wang and 
colleagues [69] reported similar results in that overall obesity (reflected by higher BMI) and 
central adiposity (reflected by higher waist circumference) predicted the risk for diabetes in men. 
In brief, these studies showed that central adiposity or visceral fat and BMI are risk factors and 
predictors for diabetes.  
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The increased body mass due to obesity is also suggested to be a major contributor to 
reduced insulin sensitivity in children [70]. Obese adolescent girls were shown to have impaired 
glucose disposal and failure to increase glucose oxidation and to suppress lipid oxidation in 
response to insulin infusion [70].  
Long term positive energy balance leads to excess triglyceride in the adipose tissue and 
ectopic triglyceride storage [57]. When adipose tissue is engorged with lipid, there are increased 
circulating free fatty acids, which eventually cause ectopic lipid accumulation and loss of normal 
functions and responses in tissues other than adipose tissue. To illustrate, liver steatosis, also 
known as fatty liver, which is associated with insulin resistance and hyperinsulinemia [71] is 
commonly seen in obese [57] and type 2 diabetic individuals [72]. Kelley and coworkers [72] 
reported that fatty liver is correlated to visceral adiposity and more severe insulin resistance in 
type 2 diabetics as evidenced by significantly increased fasting plasma insulin and fatty acids in 
comparison to type 2 diabetics without fatty liver. Durante-Mangoni and colleagues [73] found 
that chronic hepatic C patients with liver steatosis had reduced adiponectin, an adipokine that has 
been shown to increase insulin sensitivity in the liver and skeletal muscle [74], compared to those 
without liver steatosis. 
Obese individuals have elevated non esterified fatty acids (NEFA), and this impairs 
normal glucose metabolism. Elevated NEFA causes insulin insensitivity in muscle by reducing 
insulin-stimulated glucose uptake [75] through the Randle cycle that reduces glucose oxidation 
[76, 77], and by reducing glucose storage as glycogen [57] through reduced glycogen synthase 
activity [76]. Elevated NEFA also causes liver insulin insensitivity by increasing hepatic glucose 
production [75], decreasing insulin-mediated uptake of glucose from the blood, and increasing 
very-low-density lipoprotein (VLDL) production [57].  
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Thiazolidinediones (TZDs) and their mechanisms of action 
 Thiazolidinediones (TZDs) are a class of oral antidiabetic drug that was developed to 
improve insulin resistance in type 2 diabetes mellitus patients [14]. TZDs improve insulin 
resistance by increasing hepatic and adipose tissue insulin sensitivity [78]. TZDs are selective 
agonists of peroxisome proliferator-activated receptor γ (PPARγ) [79], a subset of the subfamily 
PPARs of the 48-member nuclear-receptor superfamily. PPARγ is a ligand-dependent 
transcription factor that regulates target gene expression involving glucose and lipid homeostasis 
[78, 80, 81]. In the cell, PPARγ forms a heterodimer with the retinoid X receptor (RXR) [79, 81, 
82]. TZDs have high affinity binding to the PPARγ receptor, which induces conformational 
change of the heterodimer. This conformation change stabilizes the heterodimer and promotes the 
binding of PPARγ-RXR complex to the PPARγ response elements (PPRE) in target genes 
involving cellular differentiation and lipid and glucose metabolism. As a result, it increases target 
genes transcription and translation [79, 81-83]. 
PPARγ is found most abundantly in adipose tissue, but also seen in pancreatic β-cells, 
skeletal muscle, liver, colon, and activated macrophages [78, 79]. PPARγ controls the 
differentiation and proliferation of adipocytes, fatty acid uptake and storage, and insulin 
sensitivity in adipocytes [84]. TZDs cause an increase in number of small adipocytes and in 
subcutaneous adipose tissue mass [78]. When PPARγ is bound to TZDs, it promotes fatty acid 
uptake and storage in adipose tissue, and this increases adipose tissue mass. This reduces free 
fatty acid release from adipocytes, and therefore reduces the availability and uptake of free fatty 
acid by liver cells as well as lowering the triglyceride content in the liver. As a consequence, 
insulin sensitivity will be increased as elevated plasma free fatty acid concentrations are one of 
the many contributing factors to insulin resistance.  
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TZDs also increased the circulating concentrations of adiponectin, an adipokine that is 
produced by adipose tissue [78]. Serum adiponectin levels are lower in obese and type 2 diabetic 
individuals, and increased adiponectin level is associated with increased lipid oxidation, 
improved insulin action, and anti-atherogenic effects [79]. It is also proposed that TZDs increase 
insulin sensitivity by increasing insulin-stimulated glucose disposal rates in peripheral tissues 
[84]. TZDs also ameliorate the decline in β-cell function by reducing insulin concentration 
through their function to increase insulin sensitivity and/or decrease circulating free fatty acids 
[79]. 
Due to the many effects of TZDs in various tissues, it is therefore suggested that multiple 
mechanisms of action are probably involved, such as stimulating adipose tissue to store more free 
fatty acids, thereby sparing other tissues (liver, skeletal muscle, and possibly β-cells) from 
lipotoxicity [78], and increasing secretion of adiponectin from adipose tissue as well as glucose 
disposal rate in peripheral tissue, which increases insulin sensitivity in liver and muscle tissues. 
 
Rosiglitazone effectiveness and side effects 
 Rosiglitazone is an antidiabetic drug in the class of TZDs. Rosiglitazone has been shown 
to modulate blood glucose both in animal models of diabetes and in humans [85-88]. Lessard and 
others [87] found that obese Zucker rats treated with rosiglitazone for a period of 6 weeks had 
increased body mass and plasma cholesterol, but decreased plasma insulin and triglyceride levels 
as compared to the control obese rats that were not treated with rosiglitazone. When a glucose 
tolerance test was performed, obese rats treated with rosiglitazone had improved glucose 
tolerance shown by reduced glucose area under the curve. 
A study called the Diabetes Reduction Assessment with Ramipril and Rosiglitazone 
Medication (DREAM) [85] showed that 50.5% of the participants with impaired fasting glucose, 
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glucose tolerance, or both became normoglycemic after daily administration of 8 mg of 
rosiglitazone for a median of 3 years. Additionally, Miyazaki and colleagues [86] reported 
increased hepatic and peripheral tissue insulin sensitivity and reduced NEFA turnover in patients 
with 12 weeks of rosiglitazone use. They also found that fasting plasma glucose and HbA1c 
levels of type 2 diabetic patients decreased significantly after the treatment. Also, fasting NEFA 
and basal NEFA turnover decreased significantly in patients, suggesting there was improved 
adipose tissue sensitivity to insulin.  
In addition, Hanley and colleagues [88] reported a significant improvement in β-cell 
function in prediabetic subjects that received rosiglitazone treatment over time. Participants with 
impaired fasting glucose and/or impaired glucose tolerance treated with rosiglitazone for a 
median of 3 years had improved β-cell function measured by insulinogenic index (IGI) and 
proinsulin concentration (PI). Moreover, participants had increased IGI / homeostatic model 
assessment-estimated insulin resistance (HOMA-IR) and reduced PI / C-peptide concentration by 
86% and 42%, respectively. These effects persisted even after adjustment for baseline β-cell 
function. 
 Despite several studies showing the effectiveness of rosiglitazone in lowering blood 
glucose, its long-term use has been associated with increased cardiovascular risks. Kang and 
associates [19] reported that the use of rosiglitazone (4 mg/day) for 120 days resulted in weight 
gain in type 2 diabetic patients, probably due to adipogenesis. Hussein and colleagues [16] also 
demonstrated that weight gain is a significant side effect of TZDs treatment. Type 2 diabetic 
patients given 4 mg or 8 mg rosiglitazone daily for at least 2 months had weight gain of 2.9 kg 
during the first six months of the study. 
Besides weight gain, rosiglitazone is also associated with fluid retention. Hussein and 
associates [16] reported 21% of the patients treated with rosiglitazone had peripheral edema, 
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causing 4% of the affected patients to withdraw from receiving treatment. Case studies reviewed 
by Kermani and Garg [17] also reported pulmonary edema in patients treated with rosiglitazone 
(4 mg or 8 mg daily), and the discontinuation of rosiglitazone treatment resolved the problem. 
Another case study by Cekmen and colleagues [18] reported that peripheral edema presented four 
weeks after the initiation of rosiglitazone, and discontinuation of rosiglitazone treatment 
improved the condition. The authors suggested that edema may be due to the increased plasma 
volume and increased renal sodium reabsorption. The increased fluid retention or edema in 
patients taking rosiglitazone can lead to increased risk for congestive heart failure. 
Furthermore, the use of rosiglitazone is associated with other cardiovascular events risk 
and mortality. Delea and associates [23] reported that the adjusted incidence of heart failure was 
8.2% for patients treated with TZDs as compared to 5.3% for control patients. Komajda and 
associates [24] found that participants treated with metformin or sulfonylurea (oral antidiabetic 
medications) in combination with rosiglitazone had increased risk of heart failure events 
compared to participants treated with only metformin or sulfonylurea. Nissen and Wolski [25] 
reported that the rosiglitazone group had odds ratios of 1.43 for myocardial infarction and 1.64 
for death from cardiovascular causes compared to the control group after 24 weeks of treatment.  
In addition to weight gain, edema, and heart disease, the use of rosiglitazone was shown 
to have negative effects on bones. Aubert and colleagues [20] found that there was a 39% higher 
incidence of fractures in men and women treated with rosiglitazone as compared to the control 
patients. Patients treated with rosiglitazone had significantly more peripheral fractures as 
compared to the control group. Berberoglu and colleagues [21] reported a 2.56% bone loss at the 
trochanter and a 2.18% bone loss at the lumbar spine is associated with each year of rosiglitazone 
use (4 mg/day) in postmenopausal type 2 diabetic women for a period of two years. Schwartz and 
colleagues [22] reported that each year use of TZDs was associated with greater bone loss at the 
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whole body, lumbar spine, and trochanter regions in older type 2 diabetic women during the four 
year follow-up study. 
 
Combination effects of rosiglitazone with fruits/vegetables on diabetes 
 As discussed above, rosiglitazone exerts glucose-lowering properties, but also causes 
detrimental side effects with long-term use. Limited studies have investigated the hypoglycemic 
effects of combining a pharmacological option such as rosiglitazone with fruits or vegetables with 
reported glucose-lowering properties. Nivitabishekam and colleagues [89] examined the effects 
of Momordica charatia (bitter melon) in combination with rosiglitazone on lowering blood 
glucose in rats. Adult male rats were given oral extracts of bitter melon (500 mg/kg body weight 
dissolved in water), rosiglitazone (2 or 5 mg/kg body weight), and the combination of bitter 
melon (500 mg/kg body weight) with rosiglitazone (2 or 5mg/kg body weight), and control (1 
ml/kg body weight of normal saline) 30 minutes prior to glucose administration. The results of 
the glucose tolerance test revealed that all treatments showed significant reduction in serum 
glucose levels when compared to the control group. Both doses of rosiglitazone (2 or 5 mg/kg) 
combined with bitter melon were more effective in lowering blood glucose compared to their 
individual treatments. The group administered with the combination of bitter melon with a lower 
dose of rosiglitazone (2 mg/kg) showed similar glucose-lowering effect as the group given the 
higher dose of rosiglitazone (5 mg/kg). The greatest effect was seen in the group given the higher 
dose of rosiglitazone in combination with bitter melon. When similar treatments were given to 
STZ-induced diabetic rats for a period of 28 days, a similar glucose-lowering effect was seen in 
all treatment groups. The lower dose of rosiglitazone (2 mg/kg) combined with bitter melon was 
as effective as the higher dose of rosiglitazone (5 mg/kg) alone in lowering serum glucose levels. 
Again, the higher dose of rosiglitazone in combination with bitter melon was most efficacious in 
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lowering blood glucose levels. This study showed that a lower dose of rosiglitazone if combined 
with natural products with glucose-lowering properties could achieve a similar hypoglycemic 
effect as the higher dose of rosiglitazone. 
In summary, the studies discussed above demonstrate that the use of rosiglitazone, 
although effective in lowering blood glucose, has numerous side effects. Therefore, alternate 
glucose-lowering treatments should be explored. The use of a lower dose of rosiglitazone with 
natural products with hypoglycemic properties like bitter melon is another option to improve 
glucose control and reduce side effects of the drug. 
 
Fruits and their phytochemicals with glucose-lowering properties 
Many studies have focused on the beneficial health effects of fruits and vegetable due to 
their phytochemicals [90-96]. Phytochemicals have been found to possess a broad range of 
protective benefits, such as anti-inflammatory effects, prevention of infection, anti-mutagenic 
effect, and glucose-lowering effects [97].  
Studies on the glucose-lowering properties of common fruits (i.e. apples, grapes, 
blueberries, and plum) and their phytochemicals will be presented in this section. Blueberries and 
blueberry extract were shown to exert antidiabetic effect on mice [90, 91]. Prior and colleagues 
[90] reported that mice fed a high fat diet and given purified anthocyanins from blueberry (0.2 
mg/mL) in drinking water for a period of 72 days had significantly lower fasting serum glucose 
concentrations, levels similar to mice fed low fat diet. Another study conducted by DeFuria and 
colleagues [91] examined the effect of blueberry powder on insulin resistance in mice fed high fat 
diet also reported similar findings. Mice given a high fat diet (60% of energy from fat) containing 
4% blueberry powder were less insulin resistant than mice fed just the high fat diet after 8 weeks 
of treatment. The area under the curve (AUC) of the glucose tolerance test of the blueberry fed 
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mice was similar to those fed low fat diet (10% of energy from fat), and had lower blood glucose 
concentrations compared to the high fat fed mice.  
In addition to blueberries, grape seed rich in proanthocyanidin was also found to possess 
glucose-lowering properties. El-Alfy and colleagues [92] reported that alloxan-induced diabetic 
rats treated with grape seed proanthocyanidins (100 mg/kg body weight) had significantly lower 
blood glucose than non-treated diabetic rats at both 48 and 72 hours after the alloxan induction. 
Also, rats treated with grape seed proanthocyanidins had significantly higher insulin level at 72 
hours after the alloxan induction as compared to the non-treated diabetic rats. Therefore, the 
authors concluded that grape seed proanthocyanidins caused significant reduction in 
hyperglycemia induced by alloxan. Similarly, Hwang and coworkers [93] examined the effects of 
grape seed extract on blood glucose in type 2 diabetic mice. Diabetic mice (db/db) gavaged with 
grape seed extract (50 mg/ kg body weight) for 8 weeks had lower HbA1c level than the non-
treated db/db mice, and had significantly lower blood glucose concentrations. 
Apples contain high concentrations of flavonoids and a variety of other phytochemicals 
[98]. Apple consumption may be associated with lower risk of diabetes. Higher quercetin intake, 
a major component of the apple peel, was also associated with a trend toward decreased risk for 
type 2 diabetes [94]. Johnston and colleagues [95] examined the effect of apple juice in the acute 
modification of glucose tolerance. They reported significant reduction in plasma glucose 
concentration and total AUC of the glucose tolerance test (between 0 and 30 minutes) in 
participants that consumed apple juice compared to the controls. 
Plums contain high concentrations of phenolic compounds, such as flavonoids [96]. 
Flavonoids have been shown to reduce blood glucose in mice with STZ-induced hyperglycemia, 
and reduce the risk of type 2 diabetes. Utsunomiya and colleagues [96] found that 1% plum-ekisu 
(Asian plum juice) mixed with drinking water of Wistar fatty rats significantly decreased food 
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consumption and body weight at 2 weeks of treatment in comparison to the control rats (water-
treated). Plum-treated rats also had significantly lowered plasma glucose levels throughout the 
glucose tolerance test compared to the control rats, and reduced plasma insulin at 60 minutes after 
the glucose load. Furthermore, plum (0.25%) reduced plasma cholesterol and increased 
adiponectin compared to the control rats. 
The studies discussed above demonstrate that fruits and their phytochemicals have 
glucose-lowering effects. Since mango is also a fruit that is rich in phytochemicals, it is therefore 
a potential natural product to aid in modulating blood glucose and other clinical parameters. 
  
Bioactive compounds in mango 
Mango (Mangifera indica L.) from the family Anacardiaceae, is an evergreen tropical 
plant [99]. Mango ranks second in terms of internationally traded tropical fruits, and fifth in total 
world production among major fruit crops [40]. It is cultivated commercially in more than 87 
countries, mainly in tropical and subtropical regions [100]. India is the main producing country, 
followed by China, Thailand, Indonesia, Pakistan, and Mexico [99]. There are hundreds of mango 
cultivars available worldwide, which all differ in size, color, flavor, seed size, and composition 
[100]. However, only a few varieties are available in the U.S. market, namely Ataulfo, Francis, 
Haden, Keitt, Kent, and Tommy Atkins (the common ones) as well as Alphonse, Edward, Kesar, 
Manila, and Palmer (found only in certain parts of the U.S.) [101]. 
Mango fruit nutrient and polyphenolic composition varies due to growth condition 
(climate), variety, harvest conditions, postharvest storage, stages of maturity [102], harvest date, 
and packaging [103]. To illustrate, total sugars increased and acidity decreased as the fruit 
ripened [104]. Sucrose content increased 1.3-fold from day 1 to day 19 (day 1 - high firmness, 
green-colored skin and light yellow pulp; day 19 - very soft texture, slightly reddish-colored skin 
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and intensely yellow pulp) postharvest, while fructose content increased from day 1 to day 5, 
followed by a decrease to basal level. Total glucose content, on the other hand, decreased 3-fold 
from day 1 to day 15. Besides that, vitamin C content decreased as fruit ripened, resulting in a 
total of 29.75 mg/100 g of reduction from unripe to ripe fruit [105].  
In addition to maturity stages, variety also affects mango nutrient and polyphenolic 
composition. Tommy Atkins variety contained the lowest average β-carotene (4.9 mg/kg mango 
puree), while the Ataulfo variety contained the highest average β-carotene (26.1 mg/kg mango 
puree) among the five examined cultivars (Tommy Atkins, Haden, Kent, Keitt, and Ataulfo) 
[106]. Higher β-carotene content was found in mango harvested at the later harvest dates. The 
average ascorbic acid concentration for the Tommy Atkins variety was 19.3 mg/100g of puree. 
Ascorbic acid concentration was either increased or decreased by the harvest dates, but there is no 
consistent trend to the changes. The average total phenolic content in the Tommy Atkins variety 
was 27.23 mg of gallic acid equivalent (GAE)/100 g of mango puree, and was similar to Haden, 
Kent, and Keitt varieties, regardless of harvest date. The Ataulfo variety contained the highest 
average total phenolic content (109.3 mg of GAE/100 g of mango puree) compared to the other 
four varieties, regardless of the harvest date. Significantly higher gallotannin contents were found 
in mango puree harvested at later dates. Ellagic acid and mangiferin contents decreased with later 
harvest date, except for the Ataulfo variety, which increased with later harvest dates. However, 
there were large fruit-to-fruit variations within the same cultivar with the same harvest location 
and date. Singh and colleagues [107] reported higher tannic acid content in ripe compared to raw 
mango fruit, regardless of variety (Deshi, Langra, Dashahari, Chausa, Amrapali, and Mallika). On 
the other hand, gallic acid and total phenolics were higher in the raw compared to the ripe fruit, 
regardless of variety. Overall, phenolic acids including tannic and gallic (at higher amounts), and 
cinnamic, vanillic, and ferulic acids (at lower amount), differed between varieties. 
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The condition of mango during harvest can also change nutrient and polyphenolic 
composition of the mango fruit. Some harvesting methods can cause mechanical injury such as 
bruising or cuts on the fruit surface [108]. This injury can cause infection and decay in the fruit, 
which could lead to low pH, sugar, ascorbic acid and low β-carotene concentration, as well as 
altered amylase and invertase enzyme activity in the mango fruit. 
Nutrient and polyphenolic concentration is also influenced by the climate, storage, and 
packaging. Mangos grown in hotter regions have higher β-carotene content [109]. Storage and 
packaging also affect nutrient composition in mango. Hymavathi and colleagues [103] found that 
total carotene and β-carotene content of a mixture of mango powder (Baneshan, Suvarnarekha, 
Baneshan+Survarnarekha, or Suvarnarekha+Totapuri) decreased significantly during storage 
regardless of packaging type or variety. The mean total carotene concentration decreased from 
5192 µg to 2458 µg (per 100 g powder) in 6 months stored at room temperature (80.6 – 89.6ºF). 
Nonetheless, overall there was smaller percent loss of total carotene in mango packaged in the 
metalized polyester (12 µm thickness) with polyethylene (40.2 µm thickness) compared to the 
polyester poly (40.2 µm thickness). The authors suggested that lower total carotene loss in 
metalized polyester polyethylene packaging was due to lower permeability of packaging material 
to oxygen and light. Besides total carotene loss, ascorbic acid also decreased significantly with 
storage. The authors also suggested this loss could be attributed to the increase in moisture 
content. The loss of ascorbic acid was more pronounced in mango packaged in the polyester poly 
(81% loss) than in the metalized polyester polyethylene (53% loss). Metalized polyester 
polyethylene material absorbed less moisture, thereby protecting ascorbic acid loss in the powder. 
These findings suggest that regardless of variety, mango powder loses significant amounts of total 
carotene and ascorbic acid with storage and this can be further exacerbated by packaging. 
There are three parts to the mango fruit: the pulp, peel, and seed. Most of the studies on 
mango have been done using the stem bark and leaves. Because mango pulp is used in this study, 
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this section will focus on mango pulp. On average, mango pulp contains approximately 1.8 g of 
fiber, 27.7 mg of vitamin C, 3894 IU of vitamin A, and about 1.12 mg/kg of vitamin E per 100 g 
of pulp, and significant amounts of polyphenolic compounds, including quercetins, gallotannins, 
and kaempferols [40]. Table 1 and Table 2 show the nutrient composition and polyphenolic 
compounds in mango pulp, respectively. 
 
Table 1: Nutrient composition of mango pulp [40] 
Component Amount (per 100g of ripe mango pulp) 
Calories 62.1 – 63.7 
Water, g 78.9 – 82.8 
Protein, g 0.36 – 0.40 
Fat, g 0.30 – 0.53 
Carbohydrates, g 16.20 – 17.18 
Fiber, g 0.85 – 1.06 
Ash, g 0.34 – 0.52 
Calcium, mg 6.1 – 12.8 
Phosphorus, mg 5.5 – 17.9 
Iron, mg 0.20 – 0.63 
Vitamin A (carotene), mg 0.135 – 1.872 
Thiamine, mg 0.020 – 0.073 
Riboflavin, mg 0.025 – 0.068 
Niacin, mg 0.025 – 0.707 
Ascorbic Acid, mg 7.8 – 172.0 
Tryptophan, mg 3 – 6 
Lysine, mg 32 – 37 
Methionine, mg 4 
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Table 2: Polyphenol composition in mango pulp  
Component Amount 
Total phenols 50 mg GAE/100g fresh weight [110] 
Total flavonoids 5.43 mg/g ripe mango pulp flour [111] 
Mangiferin 4.6 mg/kg dry matter [112] 
Anthocyanins 252.25 mg/g ripe mango pulp flour [111] 
Gallic acid ~20 μg/g ripe fresh mango [107] 
Tannic acid ~2.4 mg/g ripe fresh mango [107] 
 
Mango and diabetes 
Different parts of the mango plant (i.e. stem bark, leaves, peel, seed, and fruit) have been 
shown to have glucose-lowering properties [27-39]. As discussed earlier, the mango fruit is rich 
in nutrients and bioactive compounds such as vitamins, minerals, fibers, and phenolic compounds. 
The next section discusses the studies that examined the glucose-lowering properties of mango.  
 
Mango stem bark and leaf extract 
An early study by Aderibigbe and colleagues [27] demonstrated the anti-hyperglycemic 
effect of mango leaf aqueous extract in rats. At 30 and 60 minutes after glucose loading (1 g/kg 
body weight of 50% glucose solution), blood glucose levels were significantly reduced in 
glucose-induced hyperglycemic rats given an aqueous mango leaves extract (1 g/kg body weight) 
60 minutes before and simultaneously with glucose loading when compared to the control 
(without glucose loading) and the oral hypoglycemic agent chlorpropamide (200 mg/kg body 
weight administered simultaneously or 60 minutes before glucose loading) groups.  
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Ojewole [28] investigated the hypoglycemic effect of mango stem bark aqueous extract 
on rats. Both fasted STZ-induced diabetic and normoglycemic rats were administered mango 
stem bark aqueous extract (50, 100, 200, 400, or 800 mg/kg body weight) orally. Both treated 
normoglycemic and hyperglycemic rats had significantly lower blood glucose concentrations 
compared to the distilled water-treated control rats. The author reported that the maximal 
reduction in the blood glucose levels was at the dose of 800 mg/kg body weight.  
A recent study by Bhowmik et al. [29] also found beneficial effects of mango leaves and 
stem bark extract on glucose levels of rats. Mango leaf and stem bark aqueous (0.1 mL/kg body 
weight) and ethanol extracts (0.125 mL/kg body weight) were given to normoglycemic and STZ-
induced diabetic rats 30 minutes prior to and simultaneously with glucose load (2.5 g/kg body 
weight). Blood was drawn at different time points (0, 60, and 120 minutes for mango extracts 
given before glucose load; 0, 30, and 75 minutes for mango extracts given simultaneously with 
glucose load; and 0, 60, and 105 minutes for mango extracts given 30 minutes prior to glucose 
load). No effect was seen when both extracts were administered before, simultaneously, and prior 
to glucose load in normoglycemic rats. On the other hand, significant anti-hyperglycemic effect 
was seen in STZ-induced diabetic rats at 30 and 75 minutes when fed extracts simultaneously 
with glucose load. Only the stem bark ethanol extract showed significant anti-hyperglycemic 
effect at 105 minutes when fed before glucose load.  
Bhowmik and colleagues [29] examined the effects of mango extracts on intestinal 
absorption of glucose in fasting normoglycemic and STZ-induced diabetic rats. No significant 
change was seen in the amount of intestinal absorbed glucose of normoglycemic rats 
supplemented with either ethanol extracts of stem bark or leaves. However, glucose absorption 
was reduced (13 - 15% reduction) in STZ-induced diabetic rats supplemented with ethanol extract 
of stem bark. They concluded that the glucose-lowering effect of mango extracts may be due to 
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the inhibition of glucose absorption in the gut, and both water and ethanol extracts of stem bark 
and leaf had significant anti-hyperglycemic effect in STZ-induced diabetic rats. 
Morsi and colleagues [30] reported that aqueous extract of mango leaves possesses many 
beneficial effects. STZ administration resulted in significant body weight loss and increased 
blood glucose concentration as compared to normal rats. Aqueous leaf extracts (30, 50, and 70 
mg/d) given for 42 days significantly reduced body weight loss and blood glucose level in STZ-
induced diabetic rats compared to those not given the extract. Other clinical parameters, such as 
total cholesterol (TC), low density lipoprotein (LDL), very low density lipoprotein (VLDL), and 
triglycerides (TG), and plasma high density lipoprotein (HDL) were also improved by the extracts. 
The authors concluded that mango leaf extracts possessed anti-hyperglycemic activity and 
produced hypolipidemic effects. 
Hossain and others [31] demonstrated antidiabetic and glycogenic effects of the different 
fractions of ethanol extract of mango leaves (ethyl acetate, chloroform, and petroleum-ether 
fractions) in normal and alloxan-induced diabetic rats. All fractions of ethanol extract of mango 
leaves (at a dose of 0.1 ml/100 g of body weight) caused a reduction in fasting blood glucose in 
alloxan-induced diabetic rats with the petroleum-ether fraction causing the most reduction 
(88.77%). On the other hand, only the petroleum-ether and the chloroform fractions reduced 
blood glucose of glucose-induced hyperglycemic rats. Besides lowering blood glucose levels, 
mango fractions also improved liver glycogen level in alloxan-induced diabetic rats, with the 
petroleum-ether fraction causing the most improvement (improved to 84% compared to 49% in 
control diabetic rats). Hence, the authors concluded that fractions of mango leaf extract enhanced 
liver glycogen synthesis and cellular utilization of glucose, which can both improve glucose 
homeostasis. 
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Rawi and colleagues [32] investigated the effects of mango and guava leaf aqueous 
extracts, and their combination on STZ-induced diabetic rats. Diabetic rats were given mango, 
guava, mango and guava mixture extract (250 mg/kg body weight), or glibenclamide (0.5 mg/kg 
body weight) orally, for a period of 4 weeks. The oral glucose tolerance test showed that all 
treatments significantly decreased blood glucose concentration, when compared to the non-
treated diabetic rats. In addition to that, they reported significant reduction in liver glycogen in 
rats treated with glibenclamide, followed by the mixture, guava, and mango extracts.  
In addition to the aqueous extracts from mango leaves and stem bark, mangiferin, a 
glucosylxanthone phytochemical isolated from mango stem bark and leaf extracts [40], has also 
been reported to produce hypoglycemic effects. Muruganandan and colleagues [33] investigated 
the effect of mangiferin, extracted with ethanol from mango leaves, on hyperglycemia and 
atherogenesis in STZ-induced diabetic rats. They found that rats treated with mangiferin (10 and 
20 mg/kg) for a period of 28 days restored the body weight loss due to STZ and the effect was 
comparable to insulin (6 U/kg, i.p.) treatment. Although not to the same level as insulin, both 
doses of mangiferin significantly reduced plasma glucose concentrations. Mangiferin also 
modulated lipid profiles (reduced triglycerides, total cholesterol, and LDL levels, as well as 
increased HDL levels), comparable to insulin treatment, and significantly reduced the atherogenic 
index (calculated as (total cholesterol – HDL-C)/HDL-C). An oral glucose tolerance test at 60 
minutes after the administration of mangiferin also showed significant improvement. 
Dineshkumar and colleagues [34] also found similar results. STZ-induced rats treated with 
ethanol extracted mangiferin (10 or 20 mg/kg) for 30 days significantly restored their lost body 
weight caused by STZ when compared to the control diabetic rats. Also, the mangiferin group 
had significant reduction in fasting blood sugar level, TC, TG, and LDL compared to the diabetic 
control, and an increase in HDL level compared to the glibenclamide group (10 mg/kg). These 
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findings suggest that mangiferin is an effective hypoglycemic agent that can modulate blood 
glucose as well as lipid profiles of diabetic animals. 
 
Mango peel and kernel extract 
 Parmar and Kar [35] reported that mango peel extract had hypoglycemic and 
hypolipidemic effects in rats. Mango peel methanol extract (200 mg/kg) given orally to rats for 10 
days resulted in a significant reduction of serum levels of TC, TG, LDL, and VLDL, and an 
increase in HDL level as compared to rats fed only atherogenic diet. Furthermore, mango peel 
extract also caused a significant increase in serum insulin and a decrease in serum glucose when 
compared to the atherogenic diet fed rats. 
Petchi and colleagues [36] reported the hypoglycemic effect of mango kernel extracted 
with ethanol. Overnight fasted rats fed mango kernel extract orally (200 mg/kg of body weight) 
showed significant reduction in blood glucose when compared to control rats. Gupta and Gupta 
[37] also demonstrated similar hypoglycemic effects of mango seed ethanol extract. STZ-induced 
diabetic rats were given oral mango seed extract (30 mg/kg) for a period of 14 or 21 days. 
Diabetic rats given mango seed extract for both 14 and 21 days had lower serum glucose 
compared to the control, and levels similar to diabetic rats treated with glibenclamide, an oral 
antidiabetic drug. Moreover, mango seed extract treatment (both 14 and 21 days) normalized the 
HbA1c levels induced by STZ. Serum insulin concentration of rats given mango seed extract 
(both 14 and 21 days) was also significantly higher than control diabetic rats. In contrast, serum 
triglyceride and phospholipid were significantly reduced in mango seed extract group in 
comparison to diabetic control group. These findings showed that both mango peel and kernel 
extracts were able to modulate blood glucose level in animal model. 
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Mango pulp 
Only a few studies have investigated the glucose-lowering properties of mango pulp. 
Perpetua and Salgado [38] found that alloxan-induced diabetic rats fed Tommy Atkins variety 
mango powder for 30 days had significantly lower blood glucose compared to control diabetic 
rats. Lucas and colleagues [39] also found similar results. Mice receiving the 1% freeze-dried 
mango (by weight) incorporated into high fat diet for a period of two months had approximately 
40 - 90% lower blood glucose in comparison to mice fed high fat diet at 30 - 120 minutes during 
an oral glucose tolerance test. The total AUC of the glucose tolerance test showed that 1% mango 
diet was the most effective diet in normalizing blood glucose levels in response to a high fat diet. 
Furthermore, mice fed the 1% mango diet had similar fasting blood glucose as mice treated with 
rosiglitazone (50 ppm). In addition to the effect of 1% mango on plasma glucose, they also 
examined the effects of mango on plasma leptin and adiponectin levels, two cytokines that are 
produced by adipocytes. Leptin helps to regulate satiety and when in abundance inhibits feeding, 
and is proinflammatory and platelet proaggregatory [113]. On the other hand, increased 
concentration of adiponectin is associated with lower incidence of type 2 diabetes, and its level 
falls with weight gain and in obesity. Adiponectin is anti-inflammatory and potentially anti-
atherogenic [113]. Lucas and colleagues [39] reported significantly lower concentration of plasma 
leptin in mice receiving mango diets (1% and 10% by weight) as compared to mice receiving 
control and high fat diets. On the other hand, they reported the highest level of plasma 
adiponectin in mice fed 1% mango diet which was significantly different than mice fed high fat 
diet. Hence, the authors concluded that a small dose of mango (1% by weight) was more effective 
than rosiglitazone (approximately 4.33 mg/kg body weight), in lowering glucose level in mice 
consuming the high fat diet. 
 The few human studies that examined the effect of mango pulp on postprandial glucose 
and insulin responses in type 2 diabetic patients also suggested that mango is well tolerated in 
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diabetics, despite its sweet nature. Roongpisuthipong and colleagues [114] studied the effect of 
five tropical fruits (pineapple, mango, banana, durian, and rambutan portioned to provide 25 g of 
digestible carbohydrates) on postprandial glucose and insulin responses of female diabetic 
patients. Mango and banana had significantly smaller glucose curves than pineapple, rambutan, 
and durian. However, insulin area of mango was similar to pineapple and was lower than banana. 
These findings suggest that mango compared to the other four tropical fruits led to a smaller rise 
in postprandial glucose levels in diabetics. 
 Similarly, Contractor et al. [115] investigated the postprandial glucose response to mango, 
banana, and sapota (portioned to provide 25 g of digestible carbohydrates) in diabetic patients. 
They reported that banana caused the highest rise in blood glucose. Mango response peaked at 30 
minutes, while banana and sapota peaked at 60 minutes after ingestion. The glucose response 
with mango, banana, and sapota decreased to basal levels at 3 hours. The glucose AUC of mango 
and sapota were 76% and 85% of the AUC for banana (100%), respectively; however, they were 
not significantly different.  
 Guevarra and Panlasigui [116] studied the effect of chico, mango, pineapple, and papaya 
fruit (portioned to provide 25 g of digestible carbohydrates) on blood glucose response in type 2 
diabetic subjects. They found that chico had the highest carbohydrate content (19.1%) followed 
by mango (17.3%). The glucose tolerance test showed that chico and mango caused significantly 
lower blood glucose area than wheat bread (control) in diabetic subjects. Moreover, the glycemic 
index of chico and mango were lower than pineapple and papaya.  
 Fatema and colleagues [117] examined serum glucose and insulin response to mango and 
papaya in type 2 diabetic subjects. Mango and papaya (portioned to provide 50 g digestible 
carbohydrates) were given to diabetic subjects, and glucose and insulin responses of diabetic 
subjects were compared to a standard meal (white bread). No significant difference was seen 
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among bread, papaya, and mango in serum glucose levels of diabetic subjects in fasting and 
postprandial states. Glycemic index of papaya was similar to that of mango while insulin 
response to mango was significantly lower than papaya. Thus, the authors suggested that mango 
instead of papaya should be the recommended food for diabetics. 
 Yusof et al. [118] investigated the effect of ten tropical fruits (mango, rambutan, longan, 
sapodilla, jackfruits, papaya, watermelon, and three varieties of banana) and four temperate fruits 
(red apple, orange, grapes, and green pear) on blood glucose response in healthy subjects. All 
fruits (portioned to provide 50g digestible carbohydrates) were given to healthy subjects, and 
glucose response was compared to a reference (glucose solution). Grapes, orange, red apple, 
papaya, and watermelon caused a peak in blood glucose values at 15 minutes, while the other 
fruits and glucose peaked at 30 minutes. Banana was found to cause the largest rise of blood 
glucose response (62%) when compared to glucose (100%), whereas green pear caused the lowest 
rise (18%). The blood glucose response of other fruits was 60% for longan, 59% for rambutan 
and grapes, 54% for watermelon, 47% for orange, 45% for papaya, 41% for jackfruit, 35% for 
sapodilla and mango, and 27% for red apple. Hence, the authors concluded that sapodilla and 
mango (tropical fruits) and green pear and red apple (temperate fruits) are the most suitable fruits 
to be recommended for diabetic patients. 
Both animal and human studies indicate that mango pulp possess some glucose-lowering 
properties and led to a smaller glucose AUC, which is very similar to the effects of stem bark and 
leaf aqueous extract. Our earlier study [39] had demonstrated a beneficial effect of mango pulp in 
modulating clinical parameters in mice fed high fat diet, especially plasma glucose levels. 
Therefore, we conducted this study to confirm our earlier findings on the positive effect of mango 
in comparison to the commonly prescribed oral hypoglycemic drug, rosiglitazone. In addition to 
that, many studies had shown negative effects of rosiglitazone in long-term users. Since mango 
was previously found to have a hypoglycemic effect, another aim of this study was to determine 
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whether the addition of mango will lower the dose of rosiglitazone needed to modulate blood 
glucose and other clinical parameters. 
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CHAPTER III 
 
 
METHODOLOGY 
 
Animal treatment and care 
Fifty-six two-month old male C57BL/6 mice were purchased from Charles River 
Laboratories (Wilmington, MA). The animal care and use protocol was reviewed and approved 
by the Institutional Animal Care and Use Committee of Oklahoma State University. Mice were 
acclimated with standardized rodent pelleted diet (AIN-93M) for a week before dietary treatment 
began. After acclimation, mice were weighed and randomly divided into seven dietary treatment 
groups (n=8/group) balanced by initial body weight. Mice were maintained in a 12:12 hour light 
dark cycle in a temperature controlled room. All high fat-fed groups were fed ad libitum 
throughout the study. The control group (AIN-93M) was fed ad libitum for the first four weeks 
and controlled-feed to the average food intake of high fat-fed groups for the next four weeks. 
Mice were weighed weekly and had free access to deionized water. 
 
Dietary treatment and composition 
Mice were randomly divided into seven dietary treatment groups (n=8/group): a) control 
(AIN-93M); b) high fat (HF); c) HF + rosiglitazone (50 ppm); d) HF + 1% (w/w) freeze-
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dried mango powder; e) HF + 10% (w/w) freeze-dried mango powder; f) HF + 1% freeze-dried 
mango powder + rosiglitazone (25 ppm); and g) HF + 10% freeze-dried mango powder + 
rosiglitazone (25 ppm). The AIN-93M diet was purchased from Harlan Teklad (Indianapolis, IN) 
and contained 75.8%, 9.5% , and 14.7% of calories from carbohydrate, fat, and protein, 
respectively [119]. The HF diet was based on the formulation of Molnar et al. [120] and 
contained 27.7% carbohydrate, 58.9% fat, and 13.4% protein by calories. Tommy Atkins mangos 
were purchased from a local grocery store, peeled and the pulp was freeze-dried, ground to 
powder, analyzed for nutrient composition (Table 3), and incorporated at 1% and 10% (w/w) to 
the HF diets. Tommy Atkins variety was used because it is the most available in the U.S. All HF 
diets were prepared and mixed in-house and adjusted to have similar macronutrient composition 
as well as calcium and phosphorus content. The composition of the experimental diets is shown in 
Table 4. 
 
Intraperitoneal glucose tolerance test (IGTT) 
Intraperitoneal glucose tolerance tests (IGTTs) were performed after 30 and 60 days of 
treatment. Mice were fasted overnight but had access to deionized water. After an overnight fast, 
mice were injected intraperitoneally with 20% D-glucose solution (2 g/kg body weight). Blood 
samples were obtained from the tail vein at 0, 5, 15, 30, 60, and 120 minutes after glucose 
injection. Blood glucose concentrations were determined using an AlphaTrak™ glucometer 
(Abbott Laboratories, North Chicago, IL). The glucose AUC for each dietary treatment group was 
calculated using the trapezoidal rule [121].  
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Necropsy and tissue processing 
After 60 days on the respective dietary treatments, mice were weighed and fasted for 12 
hours before the necropsy. At necropsy, mice were anesthetized with a ketamine/xylazine 
(25.0:2.5 mg/mL) cocktail (0.15 mL/10 g of body weight). Whole body composition was 
analyzed using x-ray absorptiometry (GE Lunar PIXImus, Fitchburg, WI). Mice were killed by 
exsanguination, and blood was collected from the carotid artery into ethylenediaminetetraacetic 
acid (EDTA) coated tubes Blood was centrifuged for 20 minutes at 4,000 rpm to separate plasma, 
and plasma was stored at -80°C until further analyses.  
White adipose tissue, liver, kidneys, and spleen were weighed, snap-frozen and stored at -
80°C until further analyses. A portion of liver and white adipose tissues were fixed in 10% 
neutral buffered formalin until further analyses. 
 
Clinical analyses 
Whole blood glycated hemoglobin (HbA1c), plasma total cholesterol, glucose, high 
density lipoprotein (HDL), triglycerides (TG), non-esterified fatty acids (NEFA), and 
fructosamine concentrations were determined using a BioLis24i clinical chemistry analyzer 
(Carolina Liquid Chemistries Corporation™, Brea, CA). All reagent kits were purchased from 
Carolina Liquid Chemistries Corporation™ (Brea, CA) except for NEFA (Wako Diagnostics, 
Richmond, VA).  
Serum HbA1c concentrations were determined based on the amount of agglutination 
formed when goat anti-mouse IgG polyclonal antibody interacts with the monoclonal antibody 
added to the plasma. The amount of agglutination is proportional to the amount of HbA1c 
absorbed on the surface of latex particles, which can be measured as absorbance at 660 nm 
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wavelength. HbA1c concentrations were calculated from a standard curve (Carolina Liquid 
Chemistries Corporation™, Brea, CA). 
Plasma glucose concentrations were measured based on the absorbance at 340 nm 
wavelength of nicotinamide adenine dinucleotide plus hydrogen (NADH), a by-product of 
glucose breakdown. The increase in absorbance is directly proportional to glucose concentration 
in the plasma samples as a glucose molecule will cause a cascade of reactions that produces one 
micromole of NADH as the by-product. Glucose concentrations were calculated from a standard 
curve (Carolina Liquid Chemistries Corporation™, Brea, CA). 
Plasma cholesterol concentrations were measured based on the absorbance of 
quinoneimine, a dye formed when cholesterol reacted with p-hydroxy benzene sulfonic acid (p-
HBS) in the reagent mixture, at 500 nm wavelength. The increase in absorbance due to the 
formation of quinoneimine is directly proportional to the concentration of cholesterol in the 
plasma samples. Cholesterol concentrations were calculated from a standard curve (Carolina 
Liquid Chemistries Corporation™, Brea, CA). 
Plasma HDL-C concentrations were measured by solubilizing only the HDL lipoprotein 
particles, so that the HDL cholesterol is released to react with the cholesterol esterase and 
cholesterol oxidase to give color. The non-HDL lipoproteins are inhibited from reacting with the 
enzymes. The color that is produced is measured at 600 nm and is proportional to the amount of 
HDL-C present in the plasma samples. HDL-C concentrations were calculated from a standard 
curve (Carolina Liquid Chemistries Corporation™, Brea, CA). 
Plasma triglycerides (TG) were measured based on the absorbance of quinoneimine dye, 
a product formed when TG reacts with peroxidase. The absorbance of the quinoneimine dye 4-
aminophenazone at 505 nm is directly proportional to the concentration of TG in the plasma 
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samples. TG concentrations were calculated from a standard curve (Carolina Liquid Chemistries 
Corporation™, Brea, CA). 
Plasma fructosamine concentrations were measured based on the formation of formazan 
dye from the reduction of ketoamines to nitroblue tetrazolium (NBT) and to formazan under 
alkaline condition. The formation of formazan, measured at 505 nm wavelength, is directly 
proportional to the fructosamine concentration in the plasma samples. Fructosamine 
concentrations were calculated from a standard curve (Carolina Liquid Chemistries 
Corporation™, Brea, CA). 
Plasma non esterified fatty acids (NEFA) were measured at 550 nm wavelength based on 
the absorbance of the purple colored end product formed from the oxidative condensation of 3-
methyl-N-ethyl-N-(β-hydroxyethyl)-aniline (MEHA) with 4-aminoantipyrine. The amounts of 
NEFA in the samples were determined from the optical density and the concentrations were 
calculated from a standard curve (Wako Diagnostics, Richmond, VA). 
 
Plasma insulin 
Plasma insulin concentration was determined using an enzyme-linked immunosorbent 
assay (ELISA) kit from Millipore ™ Corporation (Billerica, MA). Microtiter plates that were pre-
coated with anti-mouse insulin monoclonal antibodies were used. Samples were added to the 
wells and unbound materials were then washed and the enzyme horseradish peroxidase was 
added. The unbound or free enzyme conjugates were washed, and the immobilized antibody-
enzyme conjugate was determined by reacting with horseradish peroxidase and 3,3’,5,5’-
tetramethylbenzidine. The reaction was stopped with hydrochloric acid and absorbance was 
measured spectrophotometrically at 450 nm wavelength and corrected at 590 nm wavelength 
using a microplate reader (Biotek Synergy HT, Winooski, VT). The absorbance is directly 
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proportional to the amount of captured molecules (insulin) in the plasma samples. The 
concentration of insulin was calculated from a standard curve (Millipore ™ Corporation, Billerica, 
MA). 
 
Liver and fecal total lipid 
 Snap-frozen liver tissue was ground into powder with a mortar and pestle under liquid 
nitrogen. Approximately 0.2 gram of the liver powder sample was weighed, transferred into a 50 
mL centrifuge tube, and extracted overnight with 25 mL of methanol:chloroform (1:2) solution. 
Fecal samples were dried, ground, and approximately 1 gram of fecal powder was weighed, and 
extracted with 10 mL methanol:chloroform (1:2) solution. Determination of liver and fecal total 
lipid was based on the procedure of Folch et al. [122]. Briefly, sulfuric acid (0.05%) was added to 
the methanol:chloroform solution, vortexed, and allowed to be separated into two phases. After 
the two phases were separated, the aqueous layer was aspirated off and the volume of the 
remaining organic layer was recorded. The organic solution was poured into a pre-weighed 
aluminum pan and had evaporated to dryness under a fume hood. After all the organic solvent 
had evaporated, pans were again dried in the oven at 100ºC, cooled, and weighed. The amount of 
liver or fecal total lipid was expressed as lipid or fecal weight (in milligram) per gram of liver or 
fecal sample.  
 
Liver and adipose tissue histology 
 Liver and white adipose tissues harvested during necropsy were fixed in 10% neutral 
buffered formalin solution until further analyses. Liver and white adipose tissues were trimmed 
and cut into smaller pieces before being processed in a Thermo Scientific Shandon Citadel 1000 
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tissue processor (Austin, TX). Immediately after processing, tissues were transferred to the 
paraffin embedding machine (Leica EG1160, Buffalo Grove, IL). Paraffin-embedded tissues were 
sectioned into 7 µm slices using a high performance microtome (Leica RM2165, Buffalo Grove, 
IL), mounted onto glass microscope slides, and air-dried. Slides were then washed with alcohol 
and toluene to remove excess paraffin, stained with hematoxylin and eosin and examined under 
the Nikon Eclipse TE2000-U Inverted Microscope (Melville, NY) at 10x magnification. The 
effect of different dietary treatments on white adipose cell sizes and the degree of steatosis in 
liver tissues were evaluated through observation. 
 
Statistical analyses 
 All values are presented as mean ± standard deviation. Statistical data were computed and 
analyzed by one-way ANOVA using SAS software version 9.2 (SAS Institute, Cary, NC). The 
general linear model (GLM) procedure was used to calculate variance and least square means, 
while the means were compared using Fisher’s least significant difference. Data are considered 
significantly different with P value less than 0.05.
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Table 3: Nutrient composition of freeze-dried Tommy Atkins mango used in the study
1
 
Parameters Content/100 g 
Calories (kcal) 379 
Calories from Total Fat (kcal) 15.8 
Fat (g) 1.75 
Carbohydrates (g) 85.8 
Dietary Fiber (g) 12.9 
Protein (g) 5.01 
Moisture (g) 4.52 
Calcium (mg) 79.2 
Phosphorus (mg) 123 
1
Nutrient composition was analyzed by NP Analytical Laboratories (St. Louis, MO).
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Table 4: Composition of the experimental diets 
 
1Tommy Atkins variety; purchased from local grocery store, peeled, and pulp was freeze-dried. 
2AIN-93M contained 75.8%carbohydrate, 9.5%fat, and 14.7%protein by calories [119]. 
3High fat diet formulation containing 27.7%carbohydrate, 58.9%fat, and 13.4%protein by calories [120]. 
4Rosiglitazone was from Cayman Chemical Company (Ann Arbor, MI) and added to the HF diets at a dose of 25 ppm 
and 50 ppm.  
5Analyzed by NP Analytical Laboratories (St. Louis, MO).
Ingredients 
AIN-93M
2 
HF
3,4 
HF + 1% Mango
4
 HF + 10% Mango
4
 
(g/kg) 
Mango pulp
1
 0 0 10 100 
Total Carbohydrate 721 370 370 370 
Cornstarch 465.69 0 0 0 
Dextrinized cornstarch 155 100 91.42 14.2 
Sucrose 100 270 270 270 
Contribution of mango 0 0 8.58 85.8 
Total Protein 140 180 180 180 
Casein 140 180 179.5 174.99 
Contribution of mango 0 0 0.5 5.01 
Total Fat 40 350 350 350 
Soybean oil 40 40 39.82 38.2 
Lard 0 310 310 310 
Contribution of mango 0 0 0.18 1.75 
Total Fiber 50 50 50 50 
Cellulose 50 50 48.71 37.1 
Contribution of mango 0 0 1.29 12.9 
Vitamin mix (AIN-93-VX) 10 10 10 10 
Total mineral mix (AIN-93-MX) 35 35 35 35 
Mineral mix (Ca-P deficient) 13.4 13.4 13.4 13.4 
Calcium carbonate 12.5 12.5 12.48 12.3 
Calcium from mango 0 0 0.0079 0.079 
Sodium phosphate, dibasic (NaH2PO4) 5.6 4.8 4.73 4.51 
Potassium phosphate, monobasic, (KH2PO4) 2.4 2 2.04 1.94 
Phosphorus from mango 0 0 0.012 0.123 
Sucrose 1.1 2.3 2.35 2.842 
Choline bitartrate 2.5 2.5 2.5 2.5 
L-cysteine 1.8 1.8 1.8 1.8 
Tert-butylhydroquinone 0.008 0.008 0.008 0.008 
Kcal/100g
5 
367 559 547 544 
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CHAPTER IV 
 
 
RESULTS 
 
Food intake, feed efficiency, body and tissue weights 
 Mice in the AIN group had the highest food intake followed by those in HF+10% mango+25 
ppm rosiglitazone, HF+10% mango, and HF+50 ppm rosiglitazone groups (Table 5). Mice that 
received HF, HF+1% mango and HF+1% mango+25 ppm rosiglitazone diets had lower food intakes. 
A similar pattern was observed with caloric intake (except the AIN group) with mice in the HF+10% 
mango+25 ppm rosiglitazone, HF+50 ppm rosiglitazone, and HF+10% mango having the highest, 
followed by HF, HF+1% mango, and HF+1% mango+25 ppm rosiglitazone groups.  
 Both doses of mango combined with 25 ppm rosiglitazone (HF+1% mango+25 ppm 
rosiglitazone and HF+10% mango+25 ppm rosiglitazone) had the highest feed efficiency. Among the 
mice fed HF diets, the rosiglitazone group (HF+50 ppm rosiglitazone) had the lowest feed efficiency, 
despite having the highest caloric intake. Mice receiving either dose of mango alone (HF+1% mango 
and HF+10% mango) had statistically similar feed efficiency to that of the HF+50 ppm rosiglitazone 
group but were also not different from the HF group. As expected, the AIN group had the lowest 
caloric intake and feed efficiency.  
All groups had similar body weight at the initiation of treatment. However, all the HF diets 
had significantly higher body weights than the AIN diet after only one week of dietary treatment 
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(Table 6 & Figure 1). The HF groups gained approximately three times more weight than the AIN-
fed mice (an average of 14 grams vs 5 grams) during the 60 days treatment. Of the HF diets, the 
HF+10% mango+25 ppm rosiglitazone had the highest weight gain, while the HF+50 ppm 
rosiglitazone had the lowest weight gain. Mice receiving the mango diets alone (HF+1% mango and 
HF+10% mango) had statistically similar weight gain and final body weight as the HF+50 ppm 
rosiglitazone group, but were also still not different from the HF group. 
There were no significant differences in the spleen and kidney weights among the treatment 
groups (Table 5). Visceral adipose tissue weight was higher in the HF-fed mice except for the HF+50 
ppm rosiglitazone group which was similar to the AIN group. A similar pattern was observed with the 
liver weight. 
 
Body composition 
 Percent body fat analyzed by x-ray absorptiometry was consistent with the visceral adipose 
tissue weight (Figure 2). Mice fed AIN and HF+50 ppm rosiglitazone groups had the lowest % body 
fat and highest % lean body mass as compared to all other dietary treatment groups. The HF+1% 
mango group had the next lowest % body fat and highest % lean mass, but was also not statistically 
different from the HF group. The combination of mango with rosiglitazone (HF+1% mango+25 ppm 
rosiglitazone and HF+10% mango+25 ppm rosiglitazone) had the most negative effect on body 
composition (higher % body fat and lower % lean mass), bone mineral content and bone mineral 
density, in which levels were significantly lower than the HF group (Table 7). 
 
 
 
44 
 
Intraperitoneal glucose tolerance test (IGTT) 
 To determine the effect of dietary treatments on glucose clearance, an IGTT was performed 
after 30 and 60 days of dietary treatment. After 30 days of treatment, there were no significant 
differences among all the treatment groups in tail blood glucose at baseline and 5 minute after 
injection of glucose solution (Figure 3a). Changes in blood glucose were observed after 15, 30, and 
60 minutes of glucose injection with all the HF-fed groups having higher blood glucose than the AIN 
group. All HF-fed groups had statistically similar blood glucose during these time points. After two 
hours of glucose injection, blood glucose of the HF-fed groups was similar to the AIN group. The 
glucose total AUC of all HF-fed groups was similar and significantly higher than AIN group after 30 
days of dietary treatment (Table 8). 
 After 60 days, there were significant differences in glucose response, which were not 
observed after 30 days of treatment (Figure 3b). Among the HF-fed mice, baseline blood glucose was 
not different among all the treatment groups after 30 days, but was different at 60 days. Baseline 
blood glucose was highest in the HF+1% mango group and lowest in the HF+50 ppm rosiglitazone 
groups. There were no significant differences in blood glucose among all the groups after 5 minutes of 
glucose injection. At subsequent time points, only the HF+50 ppm rosiglitazone group had blood 
glucose concentrations similar to the control group. Additionally, glucose was still different among 
the treatment groups after two hours post-glucose injection, an observation that is not seen after 30 
days of treatment. Total glucose AUC of the AIN and HF+50 ppm rosiglitazone groups was similar 
and lower than all other treatment groups. 
 
Plasma clinical parameters, liver and fecal total lipids 
 Statistically, significant differences in plasma lipids (i.e. total and HDL-cholesterol, and 
NEFA) among treatment groups were observed (Table 9). Mice fed the HF+1% mango+25 ppm 
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rosiglitazone diet had the highest total cholesterol level followed by the HF+10% mango and HF+1% 
mango groups. These groups did not differ from the HF group. As expected, mice fed the control diet 
had the lowest total cholesterol. HDL-C had similar pattern to that of total cholesterol with mice fed 
the HF+10% mango and HF+1% mango+25 ppm rosiglitazone groups having the highest HDL-C 
concentrations, and the AIN group having the lowest HDL-C. HDL-C levels of mice fed the HF+1% 
mango and HF+10% mango diets were not different from the HF fed mice. In terms of NEFA level, 
the HF group had the highest level while the HF+50 ppm rosiglitazone group had the lowest. Mice fed 
the HF+1% mango and HF+10% mango as well as HF+10% mango+25 ppm rosiglitazone diets had 
similar NEFA levels to both the HF and AIN groups. There were no significant differences in plasma 
triglyceride levels among the groups. 
Plasma glucose was highest in the HF+1% mango group and statistically similar to the HF 
group. All the other treatment groups except the HF+1% mango and HF+50 ppm rosiglitazone groups 
had plasma glucose that was statistically similar to the AIN group. The HF+50 ppm rosiglitazone 
group had the lowest plasma glucose (Table 9). Glycated hemoglobin is significantly higher in mice 
fed the HF+50 ppm rosiglitazone and was statistically similar to all the mango groups. The AIN group 
had the lowest HbA1c, which was statistically similar to the HF and HF+1% mango groups. There 
was no difference in fructosamine concentration among the groups. Mice in the HF+1% mango+25 
ppm rosiglitazone and HF+10% mango+25 ppm rosiglitazone groups had the highest insulin level, 
and was statistically similar to those in the HF and HF+1% mango groups. Insulin level was lowest in 
the HF+50 ppm rosiglitazone group and statistically similar to the AIN and HF+10% mango groups. 
 There were no significant differences found in liver total lipid among the treatment groups 
(Table 9). In contrast, fecal total lipid was significantly different with the AIN group having 
significantly lower fecal total lipid compared to all HF-fed groups. Among the HF-fed groups, the 
HF+1% mango group had the highest fecal lipid, albeit not statistically different from the HF and 
HF+50 ppm rosiglitazone groups. 
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Liver and adipose tissue histology 
Figure 4 shows the effects of dietary treatments on the morphology of the white adipose 
tissue. Adipose tissue histology revealed bigger adipocyte in the HF+1% mango+25 ppm rosiglitazone, 
and HF+10% mango+25 ppm rosiglitazone groups compared to the other dietary treatment groups. 
Adipocytes of the AIN and HF+50 ppm rosiglitazone groups were the smallest. Adipocytes of the 
HF+1% mango and HF+10% mango groups were in between the combination groups and the control 
group. 
Figure 5 shows the effects of dietary treatments on liver histology. Based on visual 
observation, liver histological image of the HF+1%mango+25ppm rosiglitazone group appeared to 
have the most lipid droplets (steatosis), followed by the HF group. On the other hand, the least liver 
steatosis was observed in the HF+50 ppm rosiglitazone group, similar to the AIN group. Some lipid 
droplets were observed in the livers of the HF+1% mango, HF+10% mango, and HF+10% mango+25 
ppm rosiglitazone groups. 
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Table 5: Effects of dietary treatments on food intake, feed efficiency, initial and final body weights, 
and tissue weights of mice fed high fat diet for 60 days
1
 
  AIN HF 
HF + 1% 
Mango 
HF + 10% 
Mango 
HF + 50 
ppm 
rosiglita-
zone 
HF + 1% 
Mango + 
25 ppm 
rosiglita-
zone 
HF + 10% 
Mango + 
25 ppm 
rosiglita-
zone P Value 
Food Intake 
(g/d) 
3.09 ± 
0.20
a 
2.64 ± 
0.12
c 
2.65 ± 
0.20
c 
2.89 ± 
0.22
b 
2.84 ± 
0.21
b 
2.64 ± 
0.17
c 
2.92 ± 
0.23
b 
<0.0001 
Calorie Intake 
(kcal/d) 
11.36 ± 
0.75
c 
14.77 ± 
0.69
b 
14.51 ± 
1.08
b 
15.75 ± 
1.19
a 
15.85 ± 
1.18
a 
14.45 ± 
0.95
b 
15.90 ± 
1.24
a 
<0.0001 
                            Feed Efficiency 
(g/g diet) 1.51 ± 
0.86
d 
5.41 ± 
1.37
ab 
4.14 ± 
1.62
bc 
4.60 ± 
1.36
bc 
3.22 ± 
0.64
c 
6.57 ± 
1.59
a 
6.10 ± 
1.95
a 
<0.0001 
(g/kcal diet) 0.41 ± 
0.23
d 
1.26 ± 
0.32
ab 
0.97 ± 
0.38
bc 
1.17 ± 
0.35
bc 
0.80 ± 
0.16
c 
1.53 ± 
0.37
a 
1.57 ± 
0.50
a 
<0.0001 
Body Weight (grams) 
Initial Weight 21.17 ± 
1.92 
21.18 ± 
1.85 
21.25 ± 
1.88 
21.27 ± 
1.55 
21.69 ± 
1.09 
21.35 ± 
1.42 
21.37 ± 
1.37 0.9980 
Final Weight 25.85 ± 
2.52
d 
35.47 ± 
3.70
ab 
32.24 ± 
4.02
bc 
34.59 ± 
3.97
bc 
30.83 ± 
2.20
c 
38.71 ± 
4.23
a 
39.20 ± 
4.85
a 
<0.0001 
Tissue Weights (milligrams) 
White Adipose 461.4 ± 
143.6
c 
1631.2 ± 
521.4
ab 
1275.7 ± 
622.2 
b 
1631.2 ± 
465.6
ab 
515.0 ± 
251.1
c 
1768.8 ± 
437.4
a 
1783.8 ± 
371.8
a 
<0.0001 
Liver 911.4 ± 
169.9
c
 
 1095.0 ± 
264.5
abc 
1057.1 ± 
85.0
bc 
1075.7 ± 
97.4
abc 
963.3 ± 
137.9
bc 
1316.2 ± 
326.8
a 
1215.7 ± 
391.1
ab 
0.0433 
Spleen 108.6 ± 
56.7 
87.5 ± 
19.8
 
125.0 ± 
75.0
 
82.5 ±  
16.7
 
105.0 ± 
22.6
 
75.0 ± 
26.7
 
85.0 ± 
23.9
 
0.2052 
Kidney 310.0 ± 
43.4 
350.0 ± 
36.6 
318.0 ± 
28.6 
338.8 ±  
40.2 
320.0 ± 
23.7 
334.3 ± 
29.9 
372.5 ± 
59.2 0.0681 
1
Values are mean ± SD n = 6-8/group; within a row, values that do not share the same letters are 
significantly (P<0.05) different from each other.
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Table 6: Effects of dietary treatments on weekly body weight of mice fed high fat diet
1
 
1
Values are mean ± SD n = 6-8/group; within a row, values that do not share the same letters are 
significantly (P<0.05) different from each other.
 
AIN HF 
HF + 1% 
Mango 
HF + 10% 
Mango 
HF + 50 
ppm 
rosiglita-
zone 
HF + 1% 
Mango + 
25 ppm 
rosiglita- 
zone 
HF + 10% 
Mango + 
25 ppm 
rosiglita- 
Zone 
P Value (grams) 
Initial 
weight 
21.17 ± 
1.92 
21.18 ± 
1.85 
21.25 ± 
1.88 
21.27 ± 
1.55 
21.69 ± 
1.09 
21.35 ± 
1.42 
21.37 ± 
1.37 0.9980 
Week 1 
22.86 ± 
1.50
c 
24.97 ± 
1.42
ab 
24.76 ± 
1.44
b 
25.20 ± 
2.42
ab 
24.80 ± 
1.22
b 
26.35 ± 
1.43
ab 
26.62 ± 
1.80
a 
0.0015 
Week 2 
24.14 ± 
1.28
c 
26.89 ± 
1.46
b 
26.37 ± 
1.35
b 
26.33 ± 
2.43
b 
26.11 ± 
1.12
b 
28.80 ± 
1.96
a 
28.99 ± 
2.01
a 
<0.0001 
Week 3 
23.97 ± 
1.46
d 
28.69 ± 
1.95
bc 
28.16 ± 
1.66
c 
27.96 ± 
2.37
c 
26.88 ± 
1.13
c 
30.82 ± 
2.87
ab 
31.18 ± 
2.54
a 
<0.0001 
Week 4 
23.78 ± 
1.76
d 
29.90 ± 
2.60
bc 
28.73 ± 
2.28
c 
29.00 ± 
2.75
c 
27.34 ± 
1.13
c 
31.97 ± 
3.10
ab 
32.56 ± 
2.82
a 
<0.0001 
Week 5 
23.40 ± 
1.64
d 
31.54 ± 
3.06
b 
30.17 ± 
2.56
bc 
30.40 ± 
3.28
bc 
28.28 ± 
2.02
c 
34.78 ± 
3.34
a 
34.71 ± 
3.14
a 
<0.0001 
Week 6 
23.78 ± 
1.79
d 
32.94 ± 
3.41
b 
31.21 ± 
3.10
bc 
31.40 ± 
3.24
bc 
28.49 ± 
1.49
c 
36.00 ± 
3.72
a 
36.03 ± 
3.40
a 
<0.0001 
Week 7 
24.19 ± 
1.75
d 
34.40 ± 
3.34
b 
32.10 ± 
3.75
bc 
32.75 ± 
3.61
bc 
29.41 ± 
1.60
c 
37.80 ± 
4.21
a 
38.19 ± 
3.78
a 
<0.0001 
Week 8 
24.60 ± 
1.83
e 
34.97 ± 
3.76
bc 
32.99 ± 
3.86
cd 
34.24 ± 
4.22
c 
29.78 ± 
1.70
d
 
38.27 ± 
4.12
ab 
38.94 ± 
4.32
a 
<0.0001 
Final 
weight 
25.85 ± 
2.52
d 
35.47 ± 
3.70
ab 
32.24 ± 
4.02
bc 
34.59 ± 
3.97
bc 
30.83 ± 
2.20
c 
38.71 ± 
4.23
a 
39.20 ± 
4.85
a 
<0.0001 
Total 
weight 
gain 
4.68 ± 
2.66
d 
14.29 ± 
3.62
ab 
10.99 ± 
4.31
bc 
13.32 ± 
3.94
bc 
9.14 ± 
1.82
c 
17.36 ± 
4.20
a 
17.83 ± 
5.70
a 
<0.0001 
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Figure 1: Effects of dietary treatments on weekly body weight of mice fed high fat diet
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Table 7: Effects of dietary treatments on body composition, bone mineral area (BMA), content 
(BMC), and density (BMD) of mice fed high fat diet for 60 days
1 
Para-
meters 
AIN HF 
HF + 1% 
Mango 
HF + 10% 
Mango 
HF + 50 
ppm 
rosiglita-
zone 
HF + 1% 
Mango + 
25 ppm 
rosiglita-
zone 
HF + 10% 
Mango + 
25 ppm 
rosiglita-
zone 
P value 
Lean  
mass (g) 
17.41 ± 
1.68
c 
21.91 ± 
1.48
ab 
20.53 ± 
1.85
b 
21.19 ± 
1.93
ab 
20.95 ± 
0.73
ab 
22.20 ± 
1.70
ab 
22.84 ± 
2.48
a 
<0.0001 
Fat  
mass (g) 
5.34 ± 
1.12
d 
11.54 ± 
2.44
bc 
9.46 ± 
2.76
c 
11.11 ± 
2.20
c 
6.60 ± 
1.70
d 
14.35 ± 
3.42
a 
13.98 ± 
2.78
ab 
<0.0001 
Total  
mass (g) 
 22.72 ± 
2.49
d 
 33.48 ± 
3.64
ab 
30.00 ± 
3.92
bc 
32.32 ± 
3.79
b 
 27.53 ± 
2.25
c 
36.52 ± 
4.53
a 
 36.81 ± 
4.73
a 
<0.0001 
BMD 
(mg/cm²) 
50.84 ± 
3.27
a 
50.28 ± 
0.95
a 
49.78 ± 
1.93
ab 
49.59 ± 
2.27
ab 
47.70 ± 
1.29
bc 
47.36 ± 
2.02
c 
48.06 ± 
1.90
bc 
0.0100 
BMC  
(mg) 
583.38 ± 
57.39
 a 
505.38 ± 
26.42
b 
516.57± 
58.89
b 
505.75 ± 
45.75
b 
493.83 ± 
41.66
b 
422.25 ± 
50.90
c 
430.75 ± 
32.33
c 
<0.0001 
BMA  
(cm²) 
11.46 ± 
0.50
a 
10.05 ± 
0.49
b 
10.35 ± 
0.89
b 
10.18 ± 
0.57
b 
10.35 ± 
0.78
b 
8.90 ± 
0.75
c 
8.96  ± 
0.41
c 
<0.0001 
1
Values are mean ± SD n = 6-8/group; within a row, values that do not share the same letters are 
significantly (P<0.05) different from each other.
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Figure 2: Effects of dietary treatments on % body fat and lean mass of mice fed high fat diet for 60 
days
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Figure 3 a & b: Effects of dietary treatments on intraperitoneal glucose tolerance test (IGTT) of mice 
fed high fat diet for 30 days and 60 days 
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Table 8: Effects of dietary treatments on total glucose area under the curve (AUC) of mice fed high 
fat diet for 30 days and 60 days
1 
1
Values are mean ± SD n = 6-8/group; within a row, values that do not share the same letters are 
significantly (P<0.05) different from each other. 
 
 
Total 
AUC 
AIN HF 
HF + 1% 
Mango 
HF + 10% 
Mango 
HF + 50 
ppm 
rosiglita-
zone 
HF + 1% 
Mango + 
25 ppm 
rosiglita-
zone 
HF + 10% 
Mango + 
25 ppm 
rosiglita-
zone 
P value (mg/dL)minutes 
30d 24912 ± 
4139
b 
43959 ± 
8658
a 
39722 ± 
8063
a 
42133 ± 
5884
a 
36853 ± 
8640
a 
42242 ± 
8360
a 
40568 ± 
6399
a 
<0.0001 
60d 28515 ± 
3606
b 
45739 ± 
5125
a 
47132 ± 
5443
a 
45976 ± 
9538
a 
29655 ± 
7072
b 
47809 ± 
7081
a 
47944 ± 
7883
a 
<0.0001 
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Table 9: Effects of dietary treatments on plasma clinical parameters, and liver and fecal lipids of mice fed high fat diet for 60 days
1 
Parameters AIN HF 
HF + 1% 
Mango 
HF + 10% 
Mango 
HF + 50 
ppm 
rosiglitazone 
HF + 1% 
Mango + 25 
ppm 
rosiglitazone 
HF + 10% 
Mango + 25 
ppm 
rosiglitazone P value 
Plasma 
Total cholesterol 
(mg/dL) 
83.62 ± 
26.12
c 
110.19 ± 
24.65
ab 
118.71 ± 
36.42
a 
118.25 ± 
18.62
a 
83.75 ± 
5.52
bc 
125.28 ± 
16.54
a 
107.31 ± 
28.62
abc 
0.0083 
Glucose 
(mg/dL) 
189.2 ± 
29.0
b 
219.8 ± 
43.7
ab 
235.6 ±  
32.5
a 
198.8 ± 
26.7
b 
149.2±  
48.1
c 
190.9 ±  
27.9
b 
192.9 ±  
27.8
b 
0.0018 
HDL  
(mg/dL) 
31.94 ± 
12.88
c 
43.12 ± 
7.02
ab 
41.64 ± 
12.62
ab 
45.69 ± 
3.70
a 
35.25 ± 
2.07
bc 
45.07 ±  
1.77
a 
38.88 ± 
8.53
abc 
0.0182 
Triglycerides 
(mg/dL) 
22.44 ± 
2.14 
29.88 ± 
8.68 
25.71 ±  
9.94 
28.38 ±  
4.87 
22.83 ±  
3.63 
27.93 ±  
5.27 
30.12 ±  
6.29 0.1134 
Fructosamine 
(μmol/L) 
226.00 ± 
68.29
 
215.25 ± 
30.47 
182.00 ± 
46.21 
203.62 ± 
25.42 
244.50 ± 
53.38 
217.57 ± 
46.76 
234.00 ± 
33.49 0.2231 
NEFA  
(mEq/L) 
0.65 ± 
0.12
abc 
0.74 ± 
0.08
a 
0.64 ± 
0.15
abc 
0.71 ±  
0.07
ab 
0.42 ±  
0.06
d 
0.56 ±  
0.09
c 
0.62 ±  
0.08
bc 
<0.0001 
HbA1c  
(%) 
2.96 ± 
0.70
d 
3.42 ± 
0.58
cd 
3.45 ± 
0.39
bcd 
3.94 ±  
0.28
ab 
3.98 ±  
0.38
ab 
3.98 ±  
0.43
a 
3.66 ±  
0.34
abc 
0.0006 
Insulin  
(ng/mL) 
0.27 ± 
0.03
bc 
0.34 ± 
0.05
ab 
0.34 ±  
0.09
ab 
0.27 ±  
0.01
bc 
0.24 ±  
0.05
c 
0.36 ±  
0.10
a 
0.40 ±  
0.06
a 
0.0145 
Total lipids (mg/g) 
Liver 
 
106.1 ± 
77.08 
94.6 ±  
58.4 
171.6 ±  
54.3 
105.9 ±  
53.8 
120.0 ±  
60.4 
171.2 ±  
102.8 
173.8 ±  
96.4 0.2992 
Fecal 
 
18.73 ± 
3.13
e 
49.43 ± 
2.29
abc 
54.12 ±  
4.57
a 
37.78 ± 
6.57
d 
52.82 ± 
10.62
ab 
44.53 ± 
9.15
cd 
46.03 ± 
3.89
bcd 
<0.0001 
1
Values are mean ± SD n = 6-8/group; within a row, values that do not share the same letters are significantly (P<0.05) different from each other. 
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Figure 4: Effects of dietary treatments on white adipose tissue histology of mice fed high fat diet for 
60 days
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Figure 5: Effects of dietary treatments on liver tissue histology of mice fed high fat diet for 60 days
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CHAPTER V 
 
 
DISCUSSION & CONCLUSION 
 
 Our earlier study [39] demonstrated that freeze-dried mango supplementation (1% or 
10% by weight) for 2 months decreased blood glucose and leptin, increased adiponectin, and 
improved lipid profiles of mice fed high fat diet. The 1% mango dose had clinical parameters 
comparable to the control (AIN-93M) and rosiglitazone (50 ppm) diets, and was more effective 
than the 10% mango dose in modulating the assessed clinical parameters. In the present study, we 
sought to confirm our earlier findings on the effects of mango in modulating blood glucose level. 
We also examined whether a lower dose of rosiglitazone (25 ppm) combined with mango would 
be as efficacious in improving glucose and other clinical parameters as the higher dose of 
rosiglitazone (50 ppm) alone. 
Rosiglitazone, an oral antidiabetic drug, has been shown to be associated with many side 
effects, including fluid retention [18], cardiovascular events risk [24], weight gain [16], and 
fractures [20] with long-term use. If mango combined with a lower dose of rosiglitazone is 
efficacious, this may reduce the side effects associated with long-term use of the higher dose of 
rosiglitazone. The approach of combining rosiglitazone with fruits/vegetables has been shown to 
be effective by Nivitabishekam and colleagues [89]. They investigated the glucose-lowering 
effect of the combination of a lower dose of rosiglitazone (2 mg/kg body weight) with bitter 
melon. They demonstrated that the lower dose of rosiglitazone in combination with bitter 
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melon possessed glucose-lowering properties similar to higher dose rosiglitazone (5 mg/kg body 
weight) alone. This finding indicates the effectiveness of lower dose of rosiglitazone to exert 
hypoglycemic effects if combined with a functional food such as bitter melon. Based on the 
findings of Nivitabishekam and colleagues [89] and our earlier findings on the positive effects of 
mango on blood glucose [39], it is reasonable to assume that a lower dose of rosiglitazone if 
combined with mango will have a similar hypoglycemic effect as the higher dose of rosiglitazone.  
 Our findings show that the combinations of the lower dose of rosiglitazone and mango 
(both at 1% and 10%) were not beneficial in modulating blood glucose. A previous study 
conducted by Nivitabishekam and colleagues [89] demonstrated that a lower dose of rosiglitazone 
(2 mg/kg body weight) in combination with bitter melon possessed glucose-lowering properties 
similar to a higher dose of rosiglitazone (5 mg/kg body weight) alone. The difference in our 
findings with that of Nivitabishekam and colleagues [89] cannot be explained by the difference in 
the dose of rosiglitazone. Mice in our combination diet received approximately 1.80 mg of 
rosiglitazone/kg body weight, which is close to the lower dose (2 mg/kg body weight) used by 
Nivitabishekam and colleagues [89]. The differences between these two studies may be due to a 
more potent effect of the bitter melon extract used compared to mango pulp. Nivitabishekam et al. 
[89] used a concentrated extract instead of the whole fruit. The active component of bitter melon 
extract was likely to be more concentrated than those in the freeze-dried mango pulp used in our 
study. Additionally, the bitter melon fruit might have an overall better hypoglycemic effect than 
the mango fruit. In general, there are more studies reporting beneficial effects of bitter melon fruit 
on lowering blood glucose and lipid profiles [123] compared to only a few studies on mango pulp 
[38, 39].  
In this study, we also did not observe glucose-lowering effect of the mango diets. This 
finding is not consistent with our earlier results [39] or with Perpetua and Salgado [38] who found 
significant glucose-lowering effect of various concentrations (1%, 5%, 10%, or 15% by weight) 
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of Tommy Atkins mango pulp. The difference in findings between the present study and those by 
Lucas et al. [39] and those of Perpetua and Salgado [38] may be due to the stability of the active 
compounds and nutrient in the mango pulp. In the present study, the mango pulp that was used 
was a mixture of old freeze-dried mango powder (2007 & 2009) compared to freshly ground 
freeze-dried mango powder in the study of Lucas et al. [39]. A study conducted by Hymavathi et 
al. [103] reported significant losses of total carotene and ascorbic acid with storage at room 
temperature. A review by Sivakumar et al. [108] reported a decrease in gallic acid and 
gallotannins content during storage. Although the mango powder used in this study was stored in 
a 4ºC refrigerator, extended storage (>12 months) could still have caused a significant change in 
the amount of nutrient and bioactive components. Moreover, since we used a mixture of freeze-
dried mango powder in the present study, the maturity stage of mangos used may be different. 
Several investigators have shown that mango nutrient and phenolic composition is affected by the 
maturity stage [102, 105, 109]. Growth conditions could also be a possible factor that explains 
these differences between our findings and those by Lucas et al. [39] and Perpetua and Salgado 
[38]. Mercadante and Rodriguez-Amaya [109] found that in general higher β-carotene content 
was found in mango that was grown in hotter regions. Additionally, Manthey and Perkins-Veazie 
[106] reported large fruit-to-fruit bioactive component variations within the same cultivar with 
the same harvest location and date. All the factors mentioned above could help explain the 
differences in the findings between the present study and those by Lucas et al. [39] and Perpetua 
and Salgado [38]. 
Our intraperitoneal glucose tolerance test (IGTT) also did not indicate improved glucose 
clearance with mango or its combination with rosiglitazone in mice fed HF diet. Andrikopoulos 
and colleagues [124] reported increased fasting plasma glucose and total glucose AUC in high 
fat-fed mice as compared to chow-fed control mice. Similarly, in the present study, high fat 
groups (except for the 50 ppm rosiglitazone group) had increased fasting plasma glucose and total 
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glucose AUC. These results show that high fat diets induced hyperglycemia and that 50 ppm 
rosiglitazone was able to prevent this high fat diet-induced hyperglycemia. This is not surprising 
as rosiglitazone has been shown to improve β-cell function [88] and reduce insulin resistance [86]. 
In contrast, mango (1% and 10%) and its combination with a lower dose of rosiglitazone (25 ppm) 
were not able to modulate blood glucose in mice fed high fat diets, as shown by significantly 
higher blood glucose level and total AUC as compared to the control group. Some of the factors 
discussed above may have contributed to the lack of effect of mango on glucose parameters in 
this study. 
In addition to the mango powder used, there was also difference in the mouse substrain 
used in our earlier study [39] and this study. Our earlier study [39] used C57BL/6J mice from 
Harlan Teklad (Indianapolis, IN), whereas C57BL/6 mice from Charles River Laboratories 
(Wilmington, MA) were used in the present study. C57BL/6J mice have a deletion of exons 7 - 
11 in the nicotinamide nucleotide transhydrogenase (Nnt) gene that is important for glucose 
homeostasis and for regulation of insulin secretion, while other substrains of C57BL/6 carry a 
wildtype Nnt allele [125]. Due to the deletion of Nnt, C57BL/6J mice exhibit impaired glucose 
tolerance and reduced insulin secretion, independent of obesity [126]. This gene difference may 
have contributed to the differences in the findings of the present study and those of Lucas et al. 
[39]. When C57BL/6J male mice were fed high fat (60% fat) diet for a period of 2 and 14 weeks, 
they had significantly higher peak of plasma blood glucose during a glucose tolerance test in 
comparison to the C57BL/6NJ [127], a strain similar to C57BL/6 that have an intact Nnt allele. 
Furthermore, C57BL/6J mice at 20 weeks of age when fed a high fat diet had lower weight gain 
but had significantly higher mean lean and fat mass as compared to C57BL/6NJ mice [127]. 
Unlike the C57BL/6NJ substrain, C57BL/6J mice when fed a low fat diet (10% fat) did not gain 
weight after 12 weeks of age [127]. Insulin concentration was also significantly higher in 
C57BL/6NJ compared to C57BL/6J mice fed low fat diet [127]. Although both strains responded 
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well to diet-induced obesity, these results show that different substrains of C57BL/6 exhibited 
differences in glucose homeostasis.  
Nevertheless, among the mango-treated groups, the HF+1% mango group trended toward 
improved body weight and body composition. This finding is very similar to our earlier results 
[39], in which the 1% mango diet was demonstrated to have the most effect in improving body 
weight and body composition. 
To determine the effects of the different dietary treatments on body weight and body 
composition, feed efficiency was calculated. The HF groups had higher feed efficiency (an 
average of 1.22 g/kcal diet) resulting in significantly higher body weight and total body weight 
gain compared to the control group (0.41 g/kcal diet). This finding is similar to that of 
Andrikopoulos et al. [124], where significantly more weight gain with significantly less food 
intake was seen in the high fat-fed mice as compared to the chow-fed mice due to higher energy 
content of the HF diet. Both mango diets caused lower feed efficiency, which was statistically 
comparable to the HF+50 ppm rosiglitazone group, although still not statistically different from 
the HF group. Mango may modulate body composition through the PPAR pathway as suggested 
by Lucas et al. [39] as mango contains bioactive components such as mangiferin and quercetin 
that have been reported to modulate the transactivation of PPAR isoforms [128]. 
In terms of plasma lipids, high fat diet caused an increase in plasma HDL-C, results that 
are consistent with that reported by Hayek et al.[129]. They explained this phenomenon due to 
the adaptive mechanism for increased need for HDL cholesterol ester transport rate with high fat 
feeding. The AIN group had significantly lower HDL-C in comparison with the other dietary 
treatment groups. Among the high fat-fed groups, the HF+50 ppm rosiglitazone had the lowest 
HDL-C with a level similar to the AIN group, albeit not significantly different from the HF group. 
This effect of rosiglitazone on HDL-C is in agreement with the report of Gutschi and colleagues 
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[130]. They reported decreased HDL-C level in patients given rosiglitazone (4 mg twice daily), 
and the discontinuation of rosiglitazone increased HDL-C level. Among the mango-treated 
groups, the HF+10% mango+25 ppm rosiglitazone group had the lowest plasma HDL-C 
concentration, and was statistically similar to the AIN, HF+50 ppm rosiglitazone, and HF groups. 
On the other hand, HF+10% mango had the highest plasma HDL-C level, although not 
statistically different from the HF group. These findings did not show efficacy of mango and its 
combination with rosiglitazone to modulate HDL-C concentration of mice fed high fat diet. 
Schreyer and colleagues [131] reported significant increase in plasma total cholesterol 
and triglycerides in the high fat or high cholesterol atherogenic diet when compared to the chow 
diet after 14 days of feeding. Similarly in the present study, plasma total cholesterol was 
significantly lower in the AIN group as compared to the high fat-fed groups. The HF+50 ppm 
rosiglitazone group had lower total cholesterol, but was not statistically different from the HF 
group. There was no significant difference between the mango-treated groups and the HF group 
in plasma total cholesterol. Although mango was not able to reduce plasma total cholesterol, 
mango at 1% dose was able to lower plasma free fatty acid (NEFA) to a level that was 
statistically similar to the AIN group. These findings demonstrate a moderate effect of mango, 
particularly at 1% dose in modulating lipid parameters. Combining mango with rosiglitazone 
seems not to provide additional benefit on lipid parameters of mice fed high fat diet. 
To determine if the effect of mango on body composition and lipid parameters may be 
due to decreased fat absorption, fecal lipid was assessed. Fecal lipid was increased in all high fat-
fed groups, results that are in agreement with Murase et al. [132]. The HF+1% mango group had 
the highest lipid excretion, followed by the HF+50 ppm rosiglitazone group. Among the high fat-
fed groups, final body weight tended to be inversely correlated with fecal lipid level (except for 
the HF+10% mango group, probably due to higher food intake). This result is similar to Bose and 
colleagues [133], where they reported higher fecal lipids was inversely correlated with lower 
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body weight in mice fed high fat diets. In general, groups (HF+1% mango and HF+50 ppm 
rosiglitazone groups) that had the high fecal lipid also tended to have the most beneficial effect on 
the assessed clinical parameters. This finding suggests that increased fecal fat excretion could be 
a factor for some positive effects (i.e. lower white adipose tissue weight and smaller weight gain) 
observed in the HF+ 1% mango diet on some of the clinical parameters. 
In this study, we also examined the changes in the morphology of hepatocytes and 
adipocytes. Although liver weight as well as liver total lipids of the HF group were not 
statistically different from the AIN group, histological images of liver tissue of the HF group 
show some lipid droplets in the hepatocytes, a result similar to reports from Inoue et al. [134]. On 
the contrary, little or no lipid droplet was observed in the hepatocytes of the mice fed the AIN 
diet. Among the high fat-fed groups, HF+50 ppm rosiglitazone also showed no lipid droplets in 
the hepatocytes, followed by some in the HF+1% mango, HF+10% mango, and HF+10% 
mango+25 ppm rosiglitazone groups. This observation may indicate some protective effect on 
liver steatosis of 50 ppm rosiglitazone and the 1% or 10% mango and 10% mango+25 ppm 
rosiglitazone diets.  
Unlike the liver weight, significant weight gain in the adipose tissue was observed in 
mice fed high fat diets. Histological images of the HF group also showed bigger adipocyte size 
when compared to the AIN group. This result is in agreement with Nascimento et al. [135], where 
increased epididymal fat mass and bigger adipocyte sizes were reported in the high fat-high 
sucrose fed group. Among the high fat-fed groups, the HF+50 ppm rosiglitazone had a significant 
reduction in adipose tissue weight probably due to its lower feed efficiency and smaller weight 
gain, followed by the HF+1% mango group albeit not statistically different from the HF group. 
Histological images of the AIN group revealed uniform and the smallest adipocyte size among all 
of the dietary treatment groups. As observed in the adipose tissue histology, HF+50 ppm 
rosiglitazone diet was able to prevent the expansion of adipocytes size induced by high fat 
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feeding; however, its adipocytes were more varied in shape and size. Similar to the HF+50 ppm 
rosiglitazone diet, the HF+1% or 10% mango diets were able to prevent the expansion of 
adipocyte size induced by high fat diet. Besides that, the HF+1% or 10% mango diets led to a 
more uniform adipocyte size as compared to the HF+50 ppm rosiglitazone diet. In contrast, the 
HF+1% or 10% mango +25 ppm rosiglitazone diets resulted in the highest adipose tissue weight, 
albeit not statistically different from the HF group. Correspondingly, histological images of these 
two groups also revealed bigger adipocytes with varied sizes, demonstrating ineffectiveness of 
these diets to prevent the increased adipocyte size induced by high fat feeding.  
There are several limitations in the present study. As discussed earlier, we combined 
different batches of mango powder, which had been stored at 4ºC for about 12 months or more; 
this could have caused significant changes in the amount of the nutrients as well as bioactive 
components of the mango powder, and might therefore have affected our findings. Our 
histological data also needs to be interpreted with caution because of its qualitative nature. A 
blind evaluation or quantification of the histological data may help to avoid bias.  
In conclusion, we accept the null hypothesis that a lower dose of rosiglitazone (25 ppm) 
when combined with mango was not as effective as rosiglitazone alone (50 ppm) in lowering 
blood glucose level and modulating clinical parameters of mice fed high fat diet. Future work 
should focus on the use of freshly freeze-dried mango of known origin and maturity. Furthermore, 
mango and the animal diets should be stored in tightly sealed containers in the freezer during 
extended storage. There is also a need to determine if mango consumption will improve clinical 
parameters in humans. 
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Scope and Method of Study: This study examined the effects of freeze-dried mango 
(1% or 10% by weight), a fruit rich in vitamins A and C as well as phenolic compounds, 
in modulating clinical parameters of mice fed high fat (HF) diet. The study also 
compared the effects of mango to rosiglitazone (50 ppm), a glucose-lowering drug, and 
determined if addition of mango to a lower dose of rosiglitazone (25 ppm) will have 
similar effects. Two-month old male C57BL/6 mice were randomly assigned to one of 
the seven dietary treatment groups (n=8/group) for 60 days: AIN-control (10% fat 
calories), HF (60% fat calories), HF+1% or 10% mango, HF+50 ppm rosiglitazone, 
HF+1% mango or 10% mango+25 ppm rosiglitazone. An intraperitoneal glucose 
tolerance test was performed at 30 and 60 days of treatment. Mice were sacrificed and 
soft tissues as well as blood were collected after 60 days of treatment. Body composition, 
clinical parameters (serum HbA1c, plasma glucose, cholesterol, HDL-C, fructosamine, 
insulin, and triglycerides), and total lipids (i.e. liver and fecal) were determined. 
Histology was performed on liver and white adipose tissue. 
 
Findings and Conclusions: As expected, body weight increased after the consumption 
of HF diet. Both doses of mango had similar effect on final body weight to the 
rosiglitazone group but also not statistically different from the HF group. Mango at 1% 
dose slightly improved body composition but also not statistically different from the HF 
group. Plasma free fatty acid was modulated by 1% mango but not quite to the level of 
rosiglitazone. There were no significant differences in plasma lipids and fructosamine 
among the HF-fed groups. The HF+50 ppm rosiglitazone group had the lowest glucose 
area under the curve after a glucose tolerance test. In brief, mango supplementation (1% 
or 10%) has modest effects on clinical parameters in mice fed high fat diet. Mango 
combined with a lower dose of rosiglitazone (25 ppm) was not as effective as the higher 
dose of rosiglitazone (50 ppm) in improving the assessed clinical parameters. Future 
study should use newly freeze-dried mango powder with known origin and maturity. 
Additionally, storage conditions should also be carefully controlled to determine the 
exact relationship between mango supplementation and its effects on clinical parameters. 
 
